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The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (discussed in later chapters). How-
ever, patients in hospitals tend to differ notably in terms of mortality risk. This
variability might result in additional fluctuation in the outcomes, thus masking
the effectiveness, and resulting in misapprehension of the true assessment. In this
dissertation, a systematic approach to assess clinical procedures is taken by tak-
ing into account this variability in the mortality risk and subsequently focusing




Table 2.1: In-control average run lengths of risk-adjusted CUSUM charts based
on testing odds ratio corresponding to various underlying risk distributions. 23
Table 3.1: Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3). 65
Table 3.2: Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3) for various n 66.
Table 3.3: Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3) for true non-constant Q2 67.
Table 3.4: Empirical type I error rates of the test procedures for ∆Q = 0 corre-
sponding to various underlying mortality risk distributions for both clinical pro-
cedures under H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt). 67
Table A1: Analysis of Qˆ and its corresponding standard errors using optimal (h),
Silverman (1986)’s (h1) and, Chen and Kelton (2006)’s (h2) bandwidths. 127
v
LIST OF FIGURES
Figure 2.1: Probability density functions of the monitoring statisticWt of the risk-
adjusted CUSUM chart proposed by Steiner et al. (2000) for testing H0 : Q = 1
versus HA : Q = 2 given the true odds ratio Q = 1, corresponding to mortality
risk distributions beta(1, 3) and beta(1, 5). 24
Figure 2.2: CUSUM charts to detect (a) deterioration in performance, (b) im-
provement in performance, (c) upward shift in the average mortality risk and (d)
downward shift in the average mortality risk, for a data set in which the 100
patients’ risk follow the beta(1,3) distribution, with the performance meeting ex-
pectation for the first 50 patients but had deteriorated for the last 50 patients.
25
Figure 2.3: CUSUM charts to detect (a) deterioration in performance, (b) im-
provement in performance, (c) upward shift in the average mortality risk and (d)
downward shift in the average mortality risk, for a data set in which the first 50
patients’ risk follow the beta(1,3) distribution and the last 50 patients’ risk follow
the beta(1,2.5) distribution, with the performance meeting expectation for all 100
patients. 26
Figure 2.4: CUSUM charts to detect (a) deterioration in performance, (b) im-
provement in performance, (c) upward shift in the average mortality risk and (d)
downward shift in the average mortality risk, for patients with an acute myocar-
dial infarction who are admitted to an anonymous hospital, collected as part of
the EMMACE-1 Study. 27
Figure 2.5: CUSUM charts to detect (a) deterioration in performance, (b) im-
provement in performance, (c) a upward shift in the average mortality risk and
(d) downward shift in the average mortality risk, for patients who underwent car-
diac surgeries in an anonymous hospital in UK. The dashed lines represent the
control limits. 28
Figure 2.6: CUSUM charts to detect (a) deterioration in performance, (b) im-
provement in performance, (c) a upward shift in the average mortality risk and
(d) downward shift in the average mortality risk, for patients who underwent car-
diac surgeries in an anonymous hospital in UK. 29
Figure 3.1: Penalty-reward scoreWt awarded to a surgeon according to a patient’s
pre-operative risk xt, where H0 : p0(xt)/[1− p0(xt)] = Q0xt/(1− xt) versus HA :
pA(xt)/[1− pA(xt)] = QAxt/(1− xt). 68
vi
Figure 3.2: Plot of mortality rate pˆ(xt) against mortality risk xt, and plot of
odds ratio of mortality Q against mortality risk xt after smoothing with patients
with an acute myocardial infarction who are admitted to an anonymous hospital,
collected as part of the EMMACE-1 Study. 69
Figure 3.3: Plot of odds ratio of mortality Q against mortality risk xt after smooth-
ing and plot of mortality rate pˆ(xt) against mortality risk xt, for trainee physician
and experienced physician after smoothing for patients who underwent cardiac
surgeries in an anonymous hospital in UK. 70
Figure 3.4: Plot of mortality rate p(xt) against mortality risk xt. 71
Figure 4.1: Plot of E(SMR) against average mortality risk, with the mortality risk
distribution as beta(1,β) and n = 1000. 93
Figure A1: Unsmoothed Kernel estimate pˆ(xt;h)(equation (3.4), represented by
dashed line), smoothed MSE estimate pˆ(xt) (using equation (3.6), represented by
dotted line) of mortality rate with simulated data of size n = 1000 for (a) h = 0.01,
(b) h = 0.2 and (c) h = 0.9 n−1/5 min{s, IQR/2.68} under Q = 2. 125
Figure A2: Unsmoothed Kernel estimate pˆ(xt;h)(equation (3.4), represented by
dashed line), smoothed MSE estimate pˆ(xt) (using equation (3.6), represented by
dotted line) of mortality rate with simulated data of size n = 1000 for (a) h = 0.01,
(b) h = 0.2 and (c) h = 0.9 n−1/5 min{s, IQR/2.68} under Q = 0.5. 126
vii
CHAPTER 1. GENERAL INTRODUCTION
Section 1. Introduction
The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (discussed in later chapters). How-
ever, realistically in an industrial setting where the raw materials or products may
be comparably homogeneous in nature, this is dissimilar to that for the health care
delivery. Patients in hospitals tend to differ notably in terms of pre-procedural
risk of failure, which in this dissertation, we will refer to as mortality risk. If
this variability in the mortality risk is not taken into account in the assessment
of medical practice, this variability might result in additional fluctuation in the
outcomes, thus masking the effectiveness, and resulting in misapprehension of the
true situation. Due to this variability, it does not make sense to discuss the assess-
ment of medical practice without first accounting for risk adjustment. Motivated
by the above discussion, the focus of this dissertation is on risk adjustment in
clinical procedures.
Section 2. Dissertation Organization
This dissertation is organized using the ”alternative format” of compiling
together several manuscripts prepared for submission to international journals. For
the assessment of clinical procedures, this dissertation takes a systematic approach
to assess clinical procedures by focusing on three major areas: statistical process
control, comparison of procedures, and overall quality indicators.
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Chapter 2 utilizes the fundamental techniques of statistical process control
through the introduction of risk-adjusted monitoring tools. At present, risk-
adjusted monitoring tools are only used to monitor clinical performances. But
we demonstrate that it is not sufficient to solely monitor clinical performances. As
such, a joint monitoring scheme for clinical performance and the mortality risk is
proposed. This scheme is not just necessary but also essential to avoid making er-
roneous inferences on clinical performance when the risk distribution has changed.
A new charting procedure to monitor the mortality risk distribution, specifically
the average mortality risk of patients, is also introduced.
At present, risk-adjusted analytical tools are best used as a monitoring pro-
cedure, rather than to compare clinical performances. In Chapter 3, we propose a
model-free diagnostic technique to estimate the actual mortality rates for all levels
of predicted mortality risk to assess clinical performances. Using these estimated
mortality rates, we present a set of risk-adjusted test procedures which alleviate
the problem of interpretation through the use of penalty-reward scores. We also
consider other risk-adjusted methods for this comparison.
One widely-used overall quality indicator in medical practice will be the stan-
dardized mortality ratio (SMR). However, despite being around for some time,
health service providers are still skeptical on its ability to truly identify poor-
quality providers. Chapter 4 will present various limitations of using the SMR, as
well as highlight various possibly wrong interpretations through the use of SMR.
Chapter 5 contains a general conclusion for the dissertation.
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CHAPTER 2: JOINT MONITORING
SCHEME FOR CLINICAL PERFORMANCES
AND MORTALITY RISK
SUMMARY
Measuring quality of medical practice is a key component in improving effi-
ciency in health care, such assessment is playing an increasingly prominent role in
quality management. At present, risk-adjusted monitoring tools are only used to
monitor clinical performances. Using a sensitivity analysis, as well as illustrations
using real life applications and simulated examples, we demonstrated that it is
not sufficient to solely monitor clinical performances. In this paper, we propose to
jointly monitor clinical performance and the mortality risk. This joint monitoring
is not just necessary but also essential to avoid making erroneous inferences on
clinical performance when the risk distribution has changed. We also proposed a
new charting procedure to monitor the mortality risk distribution, specifically the
average mortality risk of patients. The design of the joint monitoring scheme is
also described in detail, with an illustration based on a real data set.
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SECTION 1. INTRODUCTION
The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (Werner and Bradlow, 2006, Clarke
and Oakley, 2007, Krumholz et al., 2008, Biswas and Kalbfleisch, 2008, Steiner
and Jones, 2009). Measuring quality of medical practice is a key component in
improving efficiency in health care, such assessment is playing an increasingly
prominent role in quality management. One fundamental practice of assessment
will be that of clinical performance monitoring. In 1999, an independent body, the
UK National Institute of Clinical Excellence was established, after the UK Gen-
eral Medical Council found three doctors possibly guilty of professional misconduct
over the quality of their heart surgeries conducted. The professional misconduct
led to 29 mortalities out of 53 children who were operated at the Bristol Royal
Infirmary (2001, BBC News 1998). This depicts the importance of clinical per-
formance monitoring as timely signals of deteriorated performance can be used to
identify assignable causes and this will in turn avoid future avertible mortalities
or other adverse health issues.
Monitoring of the effectiveness of clinical procedures and physicians’ perfor-
mance has been popularized well over 50 years ago in the medical field (Armitage,
1954 and Bartholomay, 1957). Other works include Chen (1978), Kenett and
Pollak (1983), Gallus et al. (1986), Frisen and De Mare (1991), Frisen (1992),
Chen (1996), Rossi, Lampugnani and Marchi (1999), Steiner, Cook and Farewell
(1999), Steiner et al. (2000), Spiegelhalter et al. (2003), Cook et al. (2003), Grigg
and Farewell (2004), Sherlaw-Johnson et al. (2005), Sherlaw-Johnson, Wilson and
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Gallivan (2007), Grigg and Spiegelhalter (2007), Biswas and Kalbfleisch (2008),
Steiner and Jones (2009), and Gan and Tan (2010). These works show the in-
creasing importance and popularity of such monitoring schemes in the health care
industry as it is fundamental that the quality of service provided by health care
providers are consistent and acceptable.
Realistically in an industrial setting where the raw materials or products may
be comparably homogeneous in nature, this is dissimilar to that for the health care
delivery. Patients in hospitals tend to differ notably in terms of pre-procedural risk
of failure, which in this paper we will refer to as mortality risk. If this variability
in the mortality risk is not taken into account when assessing the effectiveness of a
certain clinical procedure, this variability might result in additional fluctuation in
the outcomes, thus masking the effectiveness, and resulting in misapprehension of
the true situation. Due to this variability, it does not make sense to monitor clinical
performance without risk adjustment because the physician or clinical procedure
which was only conducted on patients with high risks will tend to have a significant
lower success rate. It is therefore sensible to monitor clinical performance while
accounting for the mortality risk of patients.
Due to the necessity for risk adjustment, Lovegrove et al. (1997, 1999) and
Poloniecki, Valencia and LittleJohns (1998) proposed a simple monitoring scheme,
the variable life-adjusted display (VLAD) which plots the expected mortality count
subtracted the observed count cumulatively. This statistic plotted is intuitive and
it has gained widespread attention and adoption. Steiner et al. (2000) then pro-
posed the use of a cumulative sum (CUSUM) chart that accounts for the patient’s
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mortality risk. It is formulated based on testing the odds ratio of the mortality.
Moustakides (1986) showed that the CUSUM chart is optimal in terms of run
length performance. Moreover, Rogers et al. (2004) stated that “it has the advan-
tage of providing a formal test of an explicit hypothesis” and Spiegelhalter (2004)
also mentioned that this risk-adjusted CUSUM chart “formally provides a more
powerful test.”
However, Rogers et al. (2004) voiced their concerns about the effect of changes
in the underlying mortality risk distribution on the performance of the risk-
adjusted CUSUM chart. We demonstrate this using a real data set. The data
comprises the outcomes of patients with an acute myocardial infarction (more
commonly known as heart attack) who are admitted to an anonymous hospital,
collected as part of the NHS Research and Development funded EMMACE-1 (Eval-
uation of Methods and Management of Acute Coronary Events) Study (Dorsch et
al. 2000). The post-operative outcomes after thirty days were collected for patients
admitted over a 3-month period. The given corresponding mortality risk for each
patient was both calculated and authenticated locally at the hospital. For the
monitoring of the clinical performance, we adopt the risk-adjusted CUSUM charts
proposed by Steiner et al. (2000) (summarized in Appendix A) while for the mon-
itoring of the mortality risk distribution, we use Page (1954)’s CUSUM procedure
(summarized in Appendix B). The CUSUM charts for this data set are shown in
Figure 2.4. For the risk-adjusted CUSUM chart designed to detect improvement
in performance, it signals at both 21st and 77th patients and for that designed to
detect deterioration in performance, it signals 14 patients later at the 91th patient.
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This leads to a suspectible conclusion that the hospital showed improvement in
performance initially and yet showed a change to that of deterioration in perfor-
mance over a short period. Could this conjecture be due to other reasons? The
CUSUM chart in Figure 2.4(c) to detect an upward shift in the average mortal-
ity risk shows a change in pattern after the 76th patient, and it signals at the
102nd patient, thus showing an increase in the average mortality risk. As there
are more patients with higher mortality risk, this results in more mortalities, thus
increasing the mortality rate and reaching an erroneous impression that there is
a deterioration in performance when in fact there is evidence to indicate that the
performance is within expectation. As such, the deterioration is possibly due to
changes in the underlying mortality risk distribution, thus showing the rationality
of the earlier concerns raised by Rogers et al. (2004).
For a particular mortality risk distribution, through the adjustment for the
patients’ mortality risks, the risk-adjusted chart developed by Steiner et al. (2000)
has accounted for the variability in the mortality risk when monitoring the clinical
performance. As such, the true clinical performance is not masked. However, this
adjustment for the mortality risk of patients does not account for any changes
in the underlying mortality risk distribution. Assume that the mortality risk
distribution be modeled by beta(α, β) which is the beta distribution, parameter-
ized by shape parameters α and β with probability density function f(x;α, β) =
(1− x)(β−1)xα−1/B(α, β), where B(α, β) = ∫ 1
0
tα−1(1− t)β−1dt. From the plot of
the probability density functions of the monitoring statisticWt of the risk-adjusted
CUSUM charts for testing H0 : Q = 1 versus HA : Q = 2 given the true odds
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ratio Q = 1, in Figure 2.1, when the risk distribution changes from beta(1,3) to
beta(1,5), this will result in more patients of low risk, and a corresponding in-
crease in the proportion of negative Wt values and a decrease in the proportion of
positive Wt values. Any changes in the risk distribution will result in a change in
the probability density function of the monitoring statistic and hence the perfor-
mance of the risk-adjusted CUSUM chart will be affected. In summary, we found
that similar to most charting procedures, despite the fact that the risk-adjusted
CUSUM chart has adjusted for the patients’ mortality risks, it is still sensitive to
changes in the risk distribution.
In order not to wrongly assess clinical performance due to changes in the
risk distribution, one should jointly monitor the clinical performances and the
mortality risks. In Section 2, we further investigate the effects of changes in the
risk distribution on the performances of the risk-adjusted CUSUM charts proposed
by Steiner et al. (2000). We also show that through the use of simulated data sets
with characteristics similar to a real data set, the joint monitoring of the clinical
performances and the mortality risk is essential. In Section 3, the joint monitoring
scheme for the clinical performances and the mortality risk will be explained in
detail and demonstrated with a real data set. In Section 4, two real applications
will be provided in health care context: monitoring of clinical procedural mortality.
The conclusions and important findings will be presented in the last section.
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SECTION 2. IMPORTANCE OF JOINT MONITORING
We first investigate the sensitivity of the earlier discussed CUSUM charts to
changes in the risk distribution by comparing the in-control average run length
(ARL), by which the ARL is defined as the expected number of patients seen
until a signal is issued. The basis for determining the parameters and various
aspects of the sensitivity analysis will be to consider situations which mimics
that of a real data set analyzed in Section 1. This basis will ensure that our
sensitivity analysis studies are befitting of real-life scenarios. Since the mortality
risk is between 0 and 1 and from the previous studies of the risk distribution, the
theoretical model distribution for the real data set may be modeled as beta(1,3).
We consider changes in the underlying risk distribution to a beta distribution with
shape parameter α = 1 but with different values of β and then examine the effect
on the in-control ARL. For detecting a deterioration in the clinical performance,
we consider risk-adjusted CUSUM charts optimal in detecting QA =1.1, 1.2, 1.3,
1.4, 1.5, 2.0 and 3.0 where QA is the odds ratio considered in HA : Q = QA,
while for detecting an improvement in the clinical performance, we consider risk-
adjusted CUSUM charts optimal in detecting QA =0.9, 0.8, 0.7, 0.6, 0.5, 0.2 and
0.1. The resulting ARL’s are displayed in Table 2.1. We determine the in-control
ARL to be 100 for which the underlying mortality risk distribution is beta(1,3).
We note that as β decreases below 3, the risk distribution becomes more
skewed to the right, thus resulting in less low-risk patients and more high-risk
patients. The in-control ARL also decreases by about 3% to 13%. To the contrary,
we also note that as β increases above 3, the risk distribution becomes less skewed
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to the right, thus resulting in more low-risk patients and less high-risk patients.
The in-control ARL also increases by about 12% to 31%. This table shows clearly
how the performances of the risk-adjusted CUSUM charts are affected by changes
in the risk distribution. It is thus important to monitor clinical performances and
mortality risk jointly because any inferences drawn from a risk-adjusted CUSUM
chart alone should be treated with caution.
We also investigate two simulated data sets with characteristics similar to
the real data set as mentioned earlier, to further illustrate the importance of
simultaneous monitoring of the clinical performances and the mortality risk:
(1) A data set in which the 100 patients’ risk follow the beta(1,3) distribution,
with the clinical performance meeting expectation for the first 50 patients but
had deteriorated (with the odds of mortality increasing by 2 fold) for the last 50
patients;
(2) A data set in which the first 50 patients’ risk follow the beta(1,3) distribu-
tion and the last 50 patients’ risk follow the beta(1,2.5) distribution, with the
performance meeting expectation for all 100 patients.
For each data set, the risk-adjusted CUSUM charts for detecting deterioration
and improvement, as well as the CUSUM charts for the monitoring of the average
mortality risk, are run simultaneously. The CUSUM charts for the 2 simulated
data sets are shown in Figures 2.2 and 2.3 respectively.
For the first data set, the risk-adjusted CUSUM chart in Figure 2.2(a) shows
an obvious change in pattern after the 66th patient, and it signals at the 84th and
100th patients, with no changes in the risk distribution as shown by the charts in
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Figures 2.2(c) and 2.2(d). This shows that there is a deterioration in performance,
with no changes in the risk distribution. For the second data set, the risk-adjusted
CUSUM chart in Figure 2.3(a) also shows an obvious change in pattern after the
51st patient, and it signals at the 70th and 92th patients, thus showing that there
is also a deterioration in performance. But the CUSUM chart in Figure 2.3(c) to
detect an upward shift in the average mortality risk shows a change in pattern
after the 50th patient, and it signals at the 59th, 89th and 100th patients, thus
also showing an increase in the average mortality risk of the patients. As there
are more patients with higher mortality risk, this might result in more mortalities,
thus increasing the mortality rate in the data set and resulting in an erroneous
impression that there is a deterioration in performance. Through the two data
sets discussed, the joint monitoring of the clinical performances and the mortality
risk is not just necessary but also essential because any inferences drawn from a
risk-adjusted CUSUM chart alone could be erroneous when the risk distribution
has changed. Indeed, if joint monitoring scheme is implemented, any inferences
drawn will be more indicative of the true clinical performances.
SECTION 3. DESIGN OF JOINT MONITORING SCHEME
In this section, a joint monitoring scheme for the clinical performances and
the average mortality risk is described in detail. The illustration of this monitoring
scheme will be based on the real data analyzed in Section 1. There are 4 steps
for constructing each of the charts, whether it is to monitor either deterioration
or improvement in performance, or an upward or downward shift in the average
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mortality risk.
Step 1. Determine the mortality risk distribution of the patients.
Step 2. Decide on the false signal rate for the charts.
Step 3. Decide on a threshold of an unacceptable value for each parameter of
interest.
Step 4. Determine the control chart parameters.
Step 1. Determine the mortality risk distribution of the patients
Before a monitoring scheme is introduced, Woodall (2000) recommended that
it is evaluated using a Phase I analysis of historical data and a Phase II monitor-
ing. Steiner (2006) and Burkom (2006) also recommended using Phase I/Phase II
studies to assess any health care control charts. For the Phase I study, the risk
factors present for a group of patients, as well as their post-procedural outcomes
are recorded. Once sufficient data are collected in conjunction with an audit of the
on-going clinical performance to ensure that the process is in-control, the mortal-
ity risks for the patients may then be determined by using a rating method, such
as Parsonnet risk factors (Parsonnet, Dean and Bernstein 1989). Afterwhich, a
logistic regression model is used to convert these scores obtained from the rating
method, to a risk value between 0 and 1. The risk may also be computed based
on a logistic regression model fitted to sample data or past data set, such as the
EuroSCORE (Nashef et al., 1999) which is used to evaluate the risk of patients
for cardiac operations. Based on the risks obtained in this retrospective anal-
ysis, explanatory techniques such as probability plots and histograms, can first
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be employed to study the shape of the underlying risk distribution. Numerical
methods, such as Kolmogorov-Smirnov test, Anderson-Darling test or chi-square
goodness-of-fit test, can then be used to ascertain the risk distribution. For a beta
distribution, the parameters α and β can also be easily estimated using method-
of-moments estimates as
αˆ = x¯[x¯(1− x¯)/s2 − 1], (2.1)
βˆ = (1− x¯)[x¯(1− x¯)/s2 − 1], (2.2)
where x¯ is the sample average and s2 is the sample variance of the mortality
risks obtained in a Phase I study. For the hospital in the EMMACE-1 study that
we studied, the beta(1,3) distribution is found to provide an adequate fit to the
data. This results in a average mortality risk of 1/(1 + 3) or 25%, and it is fairly
consistent with the overall mortality rate of about 21.3%.
Step 2. Decide on the false signal rate for the charts
A false signal rate θ implies that on average, 1/θ runs will be plotted until a
signal is issued when the process is in control. This is equivalent to stating the
in-control ARL as 1/θ. Suppose the average number of patients admitted per year
is 800 and hospital administrators decide that 4 false signals per year is reasonable.
This results in a false signal rate of 4 per 800 patients, or 1 per 200 patients to be
plotted on the chart. For another scenario, if the hospital administrators decide
that 8 false signals per year is reasonable, then this results in a false signal rate
of 8 per 800 patients, or 1 per 100 patients to be plotted on the chart. This false
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signal of 1 per 100 patients would mean that on average, out of every 100 patients
admitted, the chart will issue a signal that the process might have changed even
though the process is in control.
The choice of an appropriate false signal rate θ depends primarily on the
desired Type I error rate. Spiegelhalter et al. (2003) stated that the desired Type
I error rate should reflect the relative “costs” of making the error. For example,
if we wish to avoid falsely identifying a clinical procedure is performing beyond
expectations, we will select a small Type I error rate which corresponds to a small
false signal rate. Although a low false signal rate is desirable, it is noted that a
chart with a lower false signal rate will take longer to signal when the process has
changed. This trade off should be considered carefully in the determination of an
appropriate false signal rate.
The number of patients admitted is essentially important as well. Suppose the
average number of patients admitted per year is 100 and hospital administrators
decide that the false signal rate is 1 per 200 patients. This indicates that on
average, the chart will issue a signal every 2 years even though the process is
in control. The chart will also take a long time to signal when the process has
changed. As such, if the number of patients admitted for the clinical procedure is
low, the appropriate false signal rate will usually be pre-determined higher.
For the hospital in the EMMACE-1 study that we studied, a false signal rate
of 1 per 200 patients is determined as the number of patients admitted is relatively
large. Various false signal rates have also been used in practice. For example, a
false signal rate of 1 per 400 patients was used in the monitoring of the occurrences
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of surgical wound infections (Sherlaw-Johnson et al., 2005), and a false signal rate
of 1 per 100 patients was proposed by Coory, Duckett and Sketcher-Baker (2008)
in the monitoring of the quality of hospital care using administrative data.
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Step 3. Decide on a threshold of an unacceptable value for each parameter of
interest
For the monitoring of clinical performances, the odds ratio Q0 in H0 is set to
be 1 which indicates that the patient care process is performing within expecta-
tions under current conditions. The odds ratio QA in HA is usually taken to be the
threshold of an unacceptable odds ratio for an outcome when testing for deterio-
ration or improvement. In order to detect a deterioration, it is similar to detect an
increase in the mortality rate, thus we will set QA > 1 but if the intent is to detect
an improvement, it is similar to detect a decrease in the mortality rate, thus we
will set QA < 1. Two different risk-adjusted CUSUM charts are required, with one
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for the detection of improvement and the other for detection of deterioration. This
is necessary because the monitoring statistic Wt depends on the odds ratio QA,
which is different when testing for both improvement and deterioration. Steiner et
al. (2000) proposed using odds ratio QA = 2 and 0.5 which represents halving and
doubling the odds of mortality respectively. Novick et al. (2006) provided alter-
native values of the odds ratio, QA = 3/2 and 2/3 for monitoring coronary artery
bypass graft surgical outcomes. For monitoring mortality rates in interventional
cardiology, Matheny, Ohno-Machado and Resnic (2007) used QA = 3/2 and 2 as
the study is interested in monitoring whether the mortality rates have increased.
For the hospital in the EMMACE-1 study that we studied, we determined the
thresholds for the odds ratio to be QA = 2 and 0.5.
To monitor the average mortality risk for a beta distribution, the average
mortality risk µ0 is set to be x¯, which is the sample average of the mortality risks
obtained in the Phase I study, as discussed in Step 1. If other distributions for
the mortality risk are proposed, the average mortality risk µ0 can be taken as
the average for the proposed distribution. Two different CUSUM charts are also
required, with one for the detection of an upward shift in the average mortality
risk and the other for the detection of a downward shift. The corresponding shifted
average mortality risk µ1 is set such that µ1 > µ0 and µ1 < µ0 respectively. This
is again necessary because the score Wt, as shown in Appendix B, depends on
this shifted average mortality risk µ1, which is different when testing for both an
upward shift and a downward shift. We propose to set µ1 = 1.2µ0 and µ1 = 0.8µ0
to detect an upward shift and a downward shift respectively. This will correspond
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to a 20% increase and a 20% decrease in the average mortality risk respectively.
For the hospital in the EMMACE-1 study that we studied, we determined the
thresholds for the shifted average mortality risk to be µ1 = 0.3 and 0.2, with
µ0 = 0.25.
Step 4. Determine the control chart parameters
Upon setting the false signal rate θ and the parameters of interest QA and
µ1 in HA in steps 2 and 3, the control chart parameter, specifically the upper
control limit for each chart can then be determined such that it produces the
specified in-control ARL=1/θ. To achieve this, the collocation method proposed
by Knoth (2005, 2007) is used to compute the ARL for a fixed control limit of
the chart. Details can be found in Appendix C. Alternatively, the control chart
parameters can be determined using simulation.
For the hospital in the EMMACE-1 study that we studied, the false signal
rate is set as 1 per 200 patients. We also determined that the thresholds for the
odds ratio to be QA = 0.5 and 2, and that the thresholds for the shifted average
mortality risk to be µ1 = 0.3 and 0.2 with µ0 = 0.25. With these values, the
chart parameters can be determined. The control limit of the chart for detecting
a deterioration in performance and that for detecting an improvement in perfor-
mance are determined as 2.107 and 2.000 respectively. The control limit of the
chart for the detection of an upward shift in the average mortality risk and that for
the detection of a downward shift are determined as 7.699 and 8.733 respectively.
These control limits are determined using a computer program developed by the
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authors and it is available upon request.
The resulting CUSUM charts for this example are shown in Figure 2.4. As
mentioned in the introduction, for the risk-adjusted CUSUM chart designed to
detect improvement in performance, it signals at both 21st and 77th patients
but for that designed to detect deterioration, it signals 14 patients later at the
91th patient. This leads to a suspectible conclusion that the hospital showed
improvement in performance initially and yet showed deterioration over a short
period. The CUSUM chart in Figure 2.4(c) to detect an upward shift in the
average mortality risk shows a change in pattern after the 76th patient, and it
signals at the 102nd patient, thus showing an increase in the average mortality
risk. As there are more patients with higher risk, this results in more mortalities,
thus increasing the mortality rate and resulting in an erroneous impression that
there is a deterioration in performance when there is evidence to indicate that the
performance is within expectation.
SECTION 4. REAL APPLICATIONS
To better reiterate our proposed charting procedures, illustrations for two real
applications are shown. The two real data sets are obtained from an anonymous
hospital in UK. For this data set, the patients underwent two different type of
cardiac surgery operations in the hospital and their post-operative outcomes after
thirty days were collected. The corresponding mortality risk xt for each patient
was both calculated and authenticated locally at the hospital.
For the first example, a Phase I analysis of historical data with an audit of
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the clinical performance is conducted. This is to ensure that the Phase I analysis
is conducted using data in which the clinical performance is in-control. A total of
71 patients over a period of time are considered. Using the method-of-moments
estimates in (2.1) and (2.2), αˆ = 5.162 and βˆ = 24.337. Due to low admission
rate for this type of cardiac surgery operation, the false signal rate is determined
as 1 per 50 patients. We also determine the thresholds for the odds ratio to be
QA = 2 and 0.5, and that for the shifted average mortality risk to be µ1 = 0.210
and 0.140 with µ0 = 0.175. With these information, the control limits of the chart
for detecting deterioration in performance and that for detecting improvement in
performance are determined as 1.184 and 1.072 respectively. The control limits of
the chart for the detection of an upward shift in the average mortality risk and
that for the detection of a downward shift are also determined as 1.317 and 1.419
respectively.
The Phase II monitoring is conducted subsequently for 67 patients and the
CUSUM charts for this example are shown in Figure 2.5. For the risk-adjusted
CUSUM chart designed to detect a deterioration in performance, it shows a change
in pattern after the 22nd patient, and it signals at the 39th patient, but for that
designed to detect an improvement in performance, it signals at the 64th patient.
This again leads to a suspectible conclusion that the hospital showed a deterio-
ration in performance initially and thereafter showed an improvement in perfor-
mance. The CUSUM chart in Figure 2.5(d) to detect a downward shift in the
average mortality risk shows a signal at the 63rd patient, thus showing a decrease
in the average mortality risk of the patients. Due to more patients with lower mor-
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tality risk, this might result in less mortalities, thus decreasing the mortality rate
and resulting in an erroneous impression that there might be an improvement in
performance. We can only conclude there is evidence that the hospital experiences
a deterioration in performance.
For the next example, another Phase I analysis of historical data with an audit
of the clinical performance is conducted. A total of 71 patients over a period of
time are considered. Using the method-of-moments estimates in (2.1) and (2.2),
αˆ = 1.093 and βˆ = 6.772. Due to low admission rate for this type of cardiac
surgery operation again, the false signal rate is determined as 1 per 50 patients.
We determine the thresholds for the odds ratio to be QA = 2 and 0.5, and that
for the shifted average mortality risk to be µ1 = 0.167 and 0.111 with µ0 = 0.139.
With these information, the control limits of the chart for detecting deterioration
in performance and that for detecting improvement in performance are determined
as 1.045 and 0.934 respectively. The control limits of the chart for the detection
of an upward shift in the average mortality risk and that for the detection of a
downward shift are also determined as 4.460 and 4.793 respectively.
The Phase II monitoring is conducted subsequently for 54 patients and the
CUSUM charts for this example are shown in Figure 2.6. For the risk-adjusted
CUSUM chart designed to detect an improvement in performance, it signals at the
13th and 26th patients, while the CUSUM chart designed to detect a deterioration
in performance signals at the 50th patient. We are led to a suspectible conclusion
that the hospital showed an improvement in performance initially and thereafter
showed a deterioration in performance. Looking at the CUSUM charts in Figure
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2.6(c) and 2.6(d), the CUSUM chart in Figure 2.6(d) to detect an upward shift
in the average mortality risk signals at the 18th and 30th patient, thus showing
an increase in the average mortality risk of the patients before the 30th patient.
This indicates there is evidence that the hospital is not just showing an improve-
ment in performance, it is in fact showing exemplary performance in reducing the
odds of mortality despite experiencing an increase in the average mortality risk
of the patients. However, the hospital also subsequently shows a deterioration in
performance because there is no evidence of any change in the average mortality
risk.
SECTION 5. CONCLUSIONS
Measuring quality of medical practice is a key component in improving effi-
ciency in health care, such assessment is playing an increasingly prominent role
in quality management. One fundamental practice of assessment will be that of
clinical performance monitoring. In this paper, we introduce a new charting proce-
dure to monitor the mortality risk distribution, specifically the average mortality
risk of patients. Although the proposed procedure is used to monitor the aver-
age mortality risk, with the risk modeled by a beta distribution, through slight
modifications, this charting procedure can be used for other distributions for the
risk.
More importantly, we propose to jointly monitor the clinical performances
and the mortality risk. Rogers et al. (2004) expressed their concerns about the ef-
fect of changes in the underlying mortality risk distribution on the performance of
the risk-adjusted CUSUM charts used to monitor clinical performances. By using
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a sensitivity analysis study of the effects of changes in the risk distribution on the
in-control ARL, as well as illustrations using real applications and simulated exam-
ples, our findings suggest that any inferences drawn from a risk-adjusted CUSUM
chart alone could be erroneous when the risk distribution has changed. Indeed,
if joint monitoring scheme is implemented, any inferences drawn will be more in-
dicative of the true clinical performances. The monitoring of the mortality risk
provides a better understanding for any inferences drawn from the risk-adjusted
CUSUM charts. In fact, the joint monitoring of the clinical performances and the
mortality risk is not just necessary but also essential.
The design of the joint monitoring scheme for the clinical performances and
the average mortality risk is also described in detail, with an illustration based
on a real data set. It is important to note that the implementation of the joint
monitoring scheme is able to adequately identify probable changes in the clini-
cal performances and mortality risk distribution, controlling for all possible risk-
adjusting factors. Only upon seeking out these probable changes, there can begin
a process to further improve the performances, which may include retraining of
staff or upgrading of equipment. As such, we urge that joint monitoring of the
clinical performances and the mortality risk needs to become an integral part in
the measurement of the quality of medical practice.
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Table 2.1. In-control average run lengths of risk-adjusted CUSUM charts based on
testing odds ratio corresponding to various underlying risk distributions
Risk QA = 1.1 QA = 1.2 QA = 1.3 QA = 1.4 QA = 1.5 QA = 2.0 QA = 3.0
Distribution h = 0.308 h = 0.558 h = 0.765 h = 0.940 h = 1.09 h = 1.607 h = 2.125
beta(1,2) 91 91 92 92 92 94 95
beta(1,2.5) 95 95 95 96 96 96 97
beta(1,3) 100 100 100 100 100 100 100
beta(1,4) 112 111 111 110 110 109 107
beta(1,5) 124 123 123 122 121 119 116
Risk QA = 0.9 QA = 0.8 QA = 0.7 QA = 0.6 QA = 0.5 QA = 0.2 QA = 0.1
Distribution h = 0.335 h = 0.652 h = 0.954 h = 1.242 h = 1.521 h = 2.330 h = 2.616
beta(1,2) 90 90 90 89 89 87 87
beta(1,2.5) 95 95 94 94 94 93 93
beta(1,3) 100 100 100 100 100 100 100
beta(1,4) 112 112 113 113 113 115 115
beta(1,5) 125 126 126 127 127 130 131
23






























































































Figure 2.1. Probability density functions of the monitoring statistic Wt of the risk-
adjusted CUSUM chart proposed by Steiner et al. (2000) for testing H0 : Q = 1
versus HA : Q = 2 given the true odds ratio Q = 1, corresponding to mortality
risk distributions beta(1, 3) and beta(1, 5).
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(d)
Figure 2.2. CUSUM charts to detect (a) deterioration in performance, (b) improvement
in performance, (c) upward shift in the average mortality risk and (d) downward
shift in the average mortality risk, for a data set in which the 100 patients’ risk
follow the beta(1,3) distribution, with the performance meeting expectation for
the first 50 patients but had deteriorated for the last 50 patients. The dashed lines
represent the control limits. These charts signal correctly for the deterioration in
performance, with no changes in the mortality risk distribution.
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(d)
Figure 2.3. CUSUM charts to detect (a) deterioration in performance, (b) improvement
in performance, (c) upward shift in the average mortality risk and (d) downward
shift in the average mortality risk, for a data set in which the first 50 patients’ risk
follow the beta(1,3) distribution and the last 50 patients’ risk follow the beta(1,2.5)
distribution, with the performance meeting expectation for all 100 patients. The
dashed lines represent the control limits. These charts signal incorrectly for the
deterioration in performance when in fact the signal is due to the higher risks of
the last 50 patients.
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(d)
Figure 2.4. CUSUM charts to detect (a) deterioration in performance, (b) improvement
in performance, (c) upward shift in the average mortality risk and (d) downward
shift in the average mortality risk, for patients with an acute myocardial infarction
who are admitted to an anonymous hospital, collected as part of the EMMACE-1
Study. The dashed lines represent the control limits. These charts signal for an
improvement in performance initially (see (b)) and a subsequent deterioration in
performance (see (a)), with the latter corresponding to an increase in the average
mortality risk (see (c)). Without charts (c) and (d), one might make an erroneous
conclusion that there is a deterioration in performance when there is evidence to
indicate that the performance is within expectation.
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(d)
Figure 2.5. CUSUM charts to detect (a) deterioration in performance, (b) improvement
in performance, (c) a upward shift in the average mortality risk and (d) downward
shift in the average mortality risk, for patients who underwent cardiac surgeries in
an anonymous hospital in UK. The dashed lines represent the control limits. These
charts signal for a deterioration in performance initially (see (a)) and a subsequent
improvement in performance (see (b)), with the latter corresponding to a decrease
in the average mortality risk (see (d)). Without charts (c) and (d), one might make
an erroneous conclusion that there is an improvement in performance when there
is evidence to indicate that the performance might be within expectation.
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(d)
Figure 2.6. CUSUM charts to detect (a) deterioration in performance, (b) improvement
in performance, (c) a upward shift in the average mortality risk and (d) down-
ward shift in the average mortality risk, for patients who underwent cardiac
surgeries in an anonymous hospital in UK. The dashed lines represent the
control limits. These charts signal for an improvement in performance (see
(b)) with an increase in the average mortality risk initially (see (c)), and a
subsequent deterioration in performance (see (a)). There is evidence that the
hospital is showing exemplary performance despite experiencing an increase
in the average mortality risk. However, the hospital also subsequently shows
a deterioration in performance, with no evidence of change in the average
mortality risk.
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CHAPTER 3: DIAGNOSTIC TECHNIQUES FOR INVESTIGATING
MORTALITY RATES AND RISK-ADJUSTED METHODS FOR
COMPARING TWO OR MORE CLINICAL PROCEDURES
WITH VARIABLE DEGREE IN PERFORMANCE
DIFFERENCES ACROSS MORTALITY RISKS
SUMMARY
The evolution of the assessment of medical practice has been speeding up
tremendously. At present, risk-adjusted analytical tools are best used as a moni-
toring procedure, rather than to compare clinical performances. In this paper, we
propose a model-free diagnostic technique to estimate the actual mortality rates
for all levels of predicted mortality risk to assess clinical performances. Using
the estimated mortality rates, we present a set of risk-adjusted test procedures
which alleviate the problem of interpretation through the use of penalty-reward
scores. We also consider other risk-adjusted methods for this comparison. Using
real data, we show how the proposed diagnostic technique and various hypothesis
test procedures can be used effectively to evaluate the performances of two clinical
procedures. A simulation study is also conducted to investigate the performances
of the proposed test procedures against a popularly-used method, the McNemar’s
test of equality of paired proportions.
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SECTION 1. INTRODUCTION
The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (Werner and Bradlow, 2006, Clarke
and Oakley, 2007, Krumholz et al., 2008). Measuring quality of medical practice
is a key component in improving efficiency in health care, such assessment is play-
ing an increasingly prominent role in quality management. In recent years, the
United States Centers for Medicare and Medicaid Services has been collaborat-
ing with various health care organizations to participate in the Hospital Quality
Alliance (2006) such that performance information are made readily accessible to
the public, payers and providers of care. It is therefore crucial that information re-
leased is reasonably accurate and fairly representative such that it is of significant
value.
But the release of such performance report cards might lead to misinterpre-
tation of the data. Patients in hospitals tend to differ notably in terms of pre-
operative risk of procedural failure, which in this paper we will refer to as mortality
risk. If this variability in the mortality risk is not taken into account when as-
sessing a particular physician’s performance or effectiveness of a certain clinical
procedure, this variability might result in additional fluctuation in the outcomes,
thus masking the effect of the true performance of the physician or effectiveness
of the clinical procedure, and resulting in misapprehension of the true situation.
For example, if a particular physician or clinical procedure has a relatively low
mortality rate, it will give an impression that this physician is highly skilled or
this clinical procedure is effective, and vice versa. As such, the New York State
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Department of Health (2008) do not just publish raw mortality rates, they also
publish “risk-adjusted” mortality rates, which is an indication of what a physi-
cian’s mortality rate would have been, had he or she treated patients identical to
the state’s average.
To ensure that such mortality risks are taken into account, McNemar’s (1947)
test of equality of paired proportions is usually employed. For example, Chen,
Connors and Garland (2008) studied 201 patients, matching each of these 201
patients to another patient having the closest propensity score. The propensity
score in this study is the probability of a patient of having an order initiated
in the ICU to withhold life-supporting therapies. This matching procedure re-
sulted in the matched pairs being well-balanced with respect to all the potentially
confounding variables. Some other reported applications of the McNemar’s test
include Maxwell (1970), Cardozo et al. (1980), Altman et al. (1983), Seeman et
al. (1983), Schatzkin et al. (1987), Uhlmann, Pearhman and Cain (1988), Schwartz
et al. (1991), Greinacher et al. (1994), Johnston et al. (1995), Egger et al. (1997),
Kuipers et al. (1996), Scott, Besag and Neville (1999), Dickerson et al. (1999),
Dooley et al. (2001), Koopmans et al. (2008), Berger et al. (2008), Quigley et
al. (2008), Yan et al. (2008) and Boccasanta et al. (2009). It is interesting to note
that the McNemar’s test only focuses on the matched pairs in which the outcomes
differ for the members of the pairs, more commonly known as the discordant pairs.
This indicates that the matched pairs in which the outcome is the same for each
member of the pairs, or the concordant pairs, are not utilized in the assessment,
thus possibly losing valuable information from the data. Moreover, it is also im-
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portant to note that in order for the matching procedure to be conducted, it is
inefficient through the implementation of such a procedure. For example, in Chen,
Connors and Garland (2008), the initial number of patients observed was 2211.
But in order to achieve balanced groups for the comparison, only 402 patients
were studied. This implied that information from more than 80% of the initially
observed patients was not taken into account. The loss in information also results
in a loss in power of the McNemar’s test. This is shown by the results in Table
3.1 obtained from our simulation study which is befitting of a real-life scenario.
Although the use of matched pairs will take into account of the mortality
risks and thus resulting in well-balanced pairs with respect to all the potentially
confounding variables, it is assumed that the effect of the true performance of the
clinical procedure is the same (that is, the degree of the differences between each
pair is the same) regardless of the mortality risks. But this assumption does not
always hold. For example, it is possible that a certain clinical procedure works
well on patients of lower risk but might not be as effective on patients of higher
risk. One such scenario will be present in the treatment of coronary heart disease.
Coronary angioplasty is the therapeutic procedure to treat coronary arteries of
the heart that are narrowed. It is accomplished by inserting a small balloon
catheter into an artery in the groin or arm, and this catheter is subsequently
advanced to the narrowing in the affected narrowed coronary artery. This surgical
procedure is recommended for patients of lower risk and might not be as effective
for patients of higher risk, such as patients with diabetes or patients with multiple
narrowings in multiple coronary arteries. Another surgical procedure, coronary
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artery bypass graft (CABG) surgery is usually conducted on patients of higher
risk. This procedure creates new routes around narrowed and blocked arteries,
thus promoting blood flow. But due to the nature of this procedure, such an open
surgery increases the amount of risks and complications faced by the patients, thus
it is not recommended for patients of lower risk. Consequently, it is important to
note that current literature of the test procedures examine the hypothesis that
assumes the degree of the differences between the two clinical procedures is the
same, such as the McNemar’s test. If the effect of the true performance of the
clinical procedure is different across the range of mortality risks, the power of
these test procedures will be greatly undermined. In fact, these test procedures
are inappropriate to be applied under such scenarios.
In Section 2, we will examine the use of logistic regression to compare per-
formances of clinical procedures. However, logistics models are usually set up by
assuming a linear relationship between the logistic function of mortality rates, and
mortality risks, which in the event of a wrong assumed model, the power of the
test will be diminished. Unlike linear regression, there is no R2 associated with a
logistic model, thus it is not simple to evaluate whether a model is wrongly used.
As such, in this section, we will also propose a model-free diagnostic technique to
evaluate the effectiveness of the clinical procedure by investigating the mortality
rates and resulting odds ratio function against the mortality risks. Inspired by
Steiner et al. (2000), we will then proceed to formulate test procedures by making
modifications to the usual logistic model. We will also show that the log-likelihood
ratio scores for a patient proposed proposed by Steiner et al. (2000) can be inter-
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preted as a penalty-reward score given to a particular clinical procedure and this
will be used to formulate an alternative risk-adjusted procedures for comparing
two or more clinical procedures. In Section 3, two real examples will be provided
in health care context: clinical procedural mortality. Using a simulation study,
the comparison of the proposed and McNemar’s test procedures will also be ana-
lyzed and their corresponding efficiencies will be presented in Section 4. This will
also allow us to illustrate the advantages of using the proposed risk-adjusted test
procedures over the McNemar’s test procedures. The conclusions and important
findings will then be presented in the last section.
SECTION 2. GENERAL APPROACH FOR PROPOSED
RISK-ADJUSTED PROCEDURE
Monitoring of the effectiveness of clinical procedures and physicians’ perfor-
mance has been popularized well over 40 years ago in the medical field (Armitage,
1954 and Bartholomay, 1957) but it was only till 1997 when Lovegrove et al. (1997,
1999) and Poloniecki, Valencia and Littlejohns (1998) independently developed
the variable life-adjusted display (VLAD) and cumulative risk-adjusted mortality
(CRAM) charts respectively, in which the mortality risk of patients is taken into
account. For the health care delivery, patients in hospitals will differ notably in
terms of mortality risk. An adjustment for prior risk has to be implemented to en-
sure that the effect of the true performance of the clinical procedure is not masked
by the variability in this prior risk.
If we let y to be the post-procedural outcome for a patient, it corresponds to
one of two possible outcomes (success or failure). We assume yt is the outcome for
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patient t. (1 if there is a mortality or 0 if a patient survives after implementation of
the clinical procedure). Notice that the outcome of the clinical procedure may not
be observed immediately after its implementation, with one example being that
for cardiac operations in which the outcome of mortality is usually determined
within 30 days from surgery. If patient t dies anytime within 30 days from the
surgery, yt will be assigned a value of 1 and if the patient survives after 30 days
from surgery, yt will be assigned a value of 0. As a result, we have the following
probability function of yt, f(yt|p) = pyt [1− p]1−yt , where p is the mortality rate.
We further assume xt to be the mortality risk for patient t and it is estimated
prior to the implementation of the clinical procedure and it depends on the risk
factors present for the patient. This risk can be determined by using a rating
method, such as Parsonnet risk factors (Parsonnet, Dean and Bernstein, 1989) for
cardiac operations. Afterwhich, a logistic regression model is used to convert these
scores obtained from the rating method, to a risk value between 0 and 1. The risk
may also be computed based on a logistic regression model fitted to sample data
or past data set, such as the EuroSCORE (Nashef et al., 1999) which is used to
evaluate the risk of patients for cardiac operations.
Section 2.1 Usual Logistic Regression Test Procedures for
Comparing Clinical Procedures
For the health care delivery, the importance to monitor the effectiveness of
clinical procedures has also been discussed, as seen from well-publicized cases
(Werner and Bradlow, 2006, Clarke and Oakley, 2007, Krumholz et al., 2008). This
will allow providers of care to investigate if there is a need for procedural changes
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promptly. For the generality of this paper, the emphasis will be placed on the
discussion of the comparison between the effectiveness of two clinical procedures.
Suppose that we are interested in comparing the performance of two clinical
procedures: Procedure 1 and Procedure 2, assuming that their performances are
not affected, inter alia by other environmental factors. A collection of samples of
the patients treated upon using each Procedure i (i = 1, 2) has been collected.
Also suppose that this set of n1 and n2 samples of bivariate data (xit, yit) has been
collected for Procedures 1 and 2 respectively, in which we observe the patient’s
mortality risk and post-procedural outcome.
In order to compare the performance of two clinical procedures, one is testing
the hypotheses, H0 : Performances of both procedures are the same versus HA :
Performances of both procedures are different. Intuitively, due to the data setting
of a dichotomous categorical dependent variable yit and a predictor variable xit,
we can utilize the usual logistic model logit[p(xit)] = β0 + β1xit. In order to
compare the performance of two clinical procedures, one can consider comparing
the following logistic models:
logit[p(xit)] = β0 + β1xit, (3.1)
versus
logit[p(xit)] = β0 + β1xit + β2I(i = 1) + β3xitI(i = 1), (3.2)
where I(i = 1) is an indicator function with a value 1 if we are appraising Proce-
dure 1, or 0 if we are appraising Procedure 2. If there is no difference between the
performances of the two procedures, this will result in (3.1) and (3.2) to be the
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same model, with β2 and β3 both being equal to 0. But if their performances are
indeed different, the pairs of logistic models will be different.
In furtherance of this comparison, one can utilize the deviance goodness-of-fit
test (McCullagh and Nelder, 1989), where (3.2) is the full (or saturated) model,
and (3.1) is the reduced model respectively. The deviance statistic for the full
model will be subtracted from the corresponding deviance statistic for the reduced






where `(β;W) is the log-likelihood statistic of that model and `(βmax;W) is the
log-likelihood statistic of a model with a parameter βi for every observation such
that the data is fitted exactly. The difference between the residual deviance for
(3.2) and (3.1) will then be tested using a χ2-distribution with the degrees of
freedom as the number of additional parameters in the full model, which is 2 in
our comparison.
It is noted from the literature that it is common that the logistic models will
utilize a linear function of the independent variable xit. As such, this method is
dependent on the model or relationship between p(xit) and xit. If a wrong model
is used, this will in turn result in a less powerful test, as shown by the simulation
studies in Section 4. Although this method is easily implemented using statistical
software packages, it is not as easy and straightforward to test for the goodness-of-
fit of each logistic models. Unlike linear regression, there is no R2 associated with
a logistic model, since residuals do not exist. As such, it is not simple to evaluate
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whether a model is wrongly used. Before a proper implementation of the logistic
regression procedure can be made, we will need to investigate the relationship
between p(xit) and xit. In the next section, we develop a model-free diagnostic
technique for this purpose.
Section 2.2 Model-Free Diagnostic Technique to Investigate Mortality Rates
Steiner et al. (2000) proposed the use of a risk-adjusted cumulative sum
(CUSUM) chart that accounts for the patient’s mortality risk. This risk-adjusted
CUSUM chart is formulated based on testing the odds ratio of the mortality of
a patient, where H0 : odds ratio = Q0 versus HA : odds ratio = QA. This
is equivalent to testing H0 : p0(xt)/[1 − p0(xt)] = Q0xt/(1 − xt) versus HA :
pA(xt)/[1− pA(xt)] = QAxt/(1− xt) with xt being the mortality risk for patient
t and the mortality rates p0(xt) and pA(xt) are functions of the mortality risk xt.
It is also noted that a scatter plot of the data (xit, yit) will not be too
informative because of the Bernoulli nature of the outcome yit, other than to
indicate that mortality rate may appear to increase with the mortality risk. It will
be more elucidative if we are able to plot p(xit) against xit, which can subsequently
be transformed to map {p(xit)[1−xit]}/{xit[1−p(xit)]} or Q(xit) against xit such
that we are able to visualize the form of the odds ratio. We will be able to
investigate if the odds ratio is a constant or a function of xit. In order to achieve
this using a model-free approach, we will implement a two-step procedure. We will
first obtain a kernel-based matching estimator pˆ(xit;h) to estimate p(xit), and by
using the plot of {pˆ(xit;h)[1−xit]}/{xit[1− pˆ(xit;h)]} or Qˆ(xit;h) against xit, we
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will be able to identify the form of the odds ratio Q(xit). This will allow us to
identify whether the odds ratio Q(xit) is a constant or a function of xit. It is also
important to note that this step does not assume any relationship between p(xit)
and xit, and is model-free.
The next step will be to obtain a smoother estimate of the odds ratio function
through the use of the mean square error (MSE) criterion upon the establishment
of the form. We can then obtain pˆ(xit) by using the smoother estimate of the odds
ratio function.
For the initial step, we will need to apply an algorithm that employs a “dis-
tance” threshold to estimate p(xit) for each xit. By using kernel-based matching
estimators which are commonly used in topological studies, we will form weighted









where K(·) is the kernel function which is a probability density function that
is symmetric about the origin and integrates to 1 over the domain, and h is a
bandwidth parameter which controls the amount of smoothing of the data to
obtain the estimate. We have investigated various kernel function K(·) devel-
oped in the literature and the Gaussian kernel function with bandwidth h =
0.9n−1/5min{s, IQR/2.68} where IQR is the sample interquartile range and s
is the sample standard deviation, proposed by Chen and Kelton (2006) provides
satisfactory smoothing performance and emanates Qˆ adequately. Details can be
found in the Appendix D.
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After we have estimated p(xit;h), we will be able to obtain a more elucidative
plot of {pˆ(xit;h)[1−xit]}/{xit[1− pˆ(xit;h)]} or Qˆ(xit;h) against xit as this enables
us to visualize the form of the odds ratio. This will allow us to differentiate
whether the odds ratio Q(xit) is a fixed constant or a function of xit, such as
Q(xit) = β0+β1 xit or Q(xit) = β0+β1 xit+β2 x2it. This will allow us to verify if
the assumption that the effect of the true performance of the clinical procedure is
the same (on the odds ratio) regardless of the mortality risks, holds. Afterwhich,







pˆ(xit;h)− Q(xit)xit1− xit +Q(xit)xit
]2
, (3.5)






1− xij + Qˆ(xij)xij
]2
, (3.6)
with respect to the odds ratio function Qˆ(·) and we will obtain a smoother estimate
Qˆ(xit) of the odds ratio function. As mentioned earlier, if need be, we can also
obtain pˆ(xit) by using Qˆ(xit), and the plot of pˆ(xit) against the mortality risk xit
to better visualize the effectiveness of the clinical procedure.
Alternatively, after one has identified the form of the odds ratio, despite the
nonlinear relationship between p(xit) and xit, it is possible to transform xit so that
the substantive relationship remains nonlinear but the form of the relationship is
linear in terms of its parameters (Berry and Feldman 1985) and utilize the logistic
regression to visualize the effectiveness of the clinical procedure.
To further elaborate, as discussed earlier, in order to compare the performance
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of two clinical procedures, one is testing the hypotheses, H0 : Performances of both
procedures are the same versus HA : Performances of both procedures are differ-
ent. It is equivalent to test H0 : Q1(xt) = Q2(xt) versus HA : Q1(xt) 6= Q2(xt),
where Qi(xt) is the odds ratio function of xt for Procedure i. Under H0 in
which there is same performance between the clinical procedures, we note that
Q1(xt) = Q2(xt) = Q(xt) and we can estimate Q(xt) by first pooling both col-
lections of samples of the patients treated upon using each Procedure i (i = 1, 2)
and identifying the form of Q(xt) through the use of the kernel-based matching
estimators in (3.4) with the Gaussian kernel function with the bandwidth param-
eter proposed by Chen and Kelton (2006), and the plot of odds ratio against xt
to determine the form of Q(xt). Finally (3.5) will be evaluated to obtain Qˆ(xt).
Section 2.3 Test Procedures Formulated from Logistic Regression
with Knowledge of the form of Q(xt)
Intuitively, from the definition of odds ratio of the mortality of a patient, we
obtained logit[p(xt)] = log[Q(xt)] + logit(xt). Upon the identification of the form
of Q(xt) as discussed earlier, if the odds ratio Q(xt) is a constant, one can consider
comparing the following logistic models:
logit[p(xit)] = β0 + β1logit(xit), (3.7)
versus
logit[p(xit)] = β0 + β1logit(xit) + β2I(i = 1), (3.8)
or if the odds ratio Q(xt) is a function of xt, by using Taylor series, one can
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consider comparing the following logistic models:
logit[p(xit)] = β0 + β1xit + β2x2it + β3logit(xit), (3.9)
versus
logit[p(xit)] = β0 + β1xit + β2x2it + β3I(i = 1)
+ β4xitI(i = 1) + β5x2itI(i = 1) + β6logit(xit),
(3.10)
where I(i = 1) is an indicator function with a value 1 if we are appraising Proce-
dure 1, or 0 if we are appraising Procedure 2. If there is no difference between the
performances of the two procedures, depending on which pairs of logistic models
are used, this will result in (3.7) and (3.8) to be the same model, with β2 being
equal to 0, or in (3.9) and (3.10) to be the same model, with β3, β4 and β5 all be-
ing equal to 0. But if their performances are indeed different, the pairs of logistic
models will be different.
Suppose the relationship between logit[p(xit)] and xit is nonlinear using the
model-free diagnostic technique proposed in the earlier section, it is possible to
transform xit so that the substantive relationship remains nonlinear but the form
of the relationship is linear in terms of its parameters (Berry and Feldman 1985),
thus the independent variable logit(xit) is introduced in the earlier logistic models,
(3.7) to (3.10).
In furtherance of the comparison, one can utilize the deviance goodness-of-fit
test (McCullagh and Nelder, 1989), where (3.8) or (3.10) is the full (or saturated)
model, and (3.7) or (3.9) is the reduced model respectively, discussed earlier. The
difference between the residual deviance for (3.8) and (3.7), or that for (3.10) and
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(3.9) will then be tested using a χ2-distribution with the degrees of freedom as the
number of additional parameters in the full model, which is 1 or 3 respectively.
Section 2.4 Test Procedures formulated from SPRT
Investigating the risk-adjusted cumulative sum (CUSUM) chart proposed by
Steiner et al. (2000), this chart is formulated based on testing the odds ratio of
the mortality of a patient, where H0 : p0(xt)/[1− p0(xt)] = Q0xt/(1− xt) versus
HA : pA(xt)/[1− pA(xt)] = QAxt/(1− xt). Usually Q0 = 1, as the estimated risk
xt is based on the current conditions before taking into account the effect of the
true performance of the clinical procedure. In order to detect an increase in the
mortality rate, we will set QA > Q0 but if the intent is to detect a decrease in
the mortality rate, we will set QA < Q0. Steiner stated that “the choice of QA is
similar to defining the minimal clinically important effect in a clinical trial.” For a
fixed value of xt, these mortality rates p0(xt) and pA(xt) are constants. By using
the sequential probability ratio test (SPRT), the possible log-likelihood ratio score














, if yt = 0.
(3.11)
Suppose we set QA > Q0 such that we are able to detect an increase in the
mortality rate (deteriorated performance). It is known that the mortality risk
for a patient has to be nonnegative. We note that for all positive values of the
mortality risk for patient t, Wt > 0 if yt = 1 and Wt < 0 if yt = 0. Moreover,
Wt is a decreasing function of xt. This is illustrated in Figure 3.1. We can view
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Wt as a penalty-reward score given to the clinical procedure, depending on the
mortality risk and the outcome of mortality. If there is a mortality, the penalty
will be large if the risk is small, and small if the risk is large. This is contrary to
when there is no mortality. The reward given will be small if the risk is small, and
large (negatively) if the risk is large.
This is similar when we set QA < Q0 such that we are able to detect a decrease
in the mortality rate (improved performance). If there is a mortality, the penalty
will be large (negatively) if the risk is small, and small (negatively) if the risk is
large. When there is no mortality, the reward given will be small (positively) if the
risk is small, and large (positively) if the risk is large. As a decision rule, larger
positive values of Wt tend to indicate stronger evidence against H0 in support of
HA.
This illustrates that the log-likelihood ratio scores Wt for a patient proposed
by Steiner et al. (2000) can be readily interpreted as a penalty-reward score given
to a particular clinical procedure. As such, we will like to propose a set of test
procedures which will alleviate the problem of interpretation of the test statistics,
specifically if we have larger positive values ofWt for one clinical procedure as com-
pared to another clinical procedure, it can be interpreted that the performances
of the two clinical procedures are different. Moreover, this penalty-reward score is
derived using the SPRT which is inspired from the classical likelihood ratio test.
This likelihood ratio test is central to the famous Neyman and Pearson (1933)
approach to statistical hypothesis testing.
As discussed earlier, the log-likelihood ratio score for patient t, Wt can be
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viewed as a penalty-reward score given to each clinical procedure, depending on
the mortality risk and the outcome of mortality. We will issue the penalty-reward














, if yit = 0,
(3.12)
where Q0 = 1 and QA = Qˆ(xit). Upon the establishment of the penalty-reward
system, there is a direct relationship between the penalty-reward scores Wit after
accounting for the outcomes yit, and the mortality risks xit asWit = gi(xit). From
(3.12), by using Taylor series, it can be shown that Wit = βi0 + βi1xit + βi2x2it +
O(x3it). The use of the quadratic form for gi(xit) is further supported by the
plots of penalty-reward scores against mortality risks in Figure 3.1. In order to
compare the performance of two clinical procedures, one can consider comparing
the following models:
Wit = β0 + β1xit + β2x2it, (3.13)
versus
Wit = β0 + β1xit + β2x2it + β3I(i = 1) + β4xitI(i = 1) + β5x
2
itI(i = 1), (3.14)
where I(i = 1) is an indicator function with a value 1 if we are appraising Proce-
dure 1, or 0 if we are appraising Procedure 2. If there is no difference between the
performances of the two procedures, (3.13) and (3.14) will yield the same model,
with β3, β4 and β5 all being equal to 0. But if their performances are indeed
different, (3.13) and (3.14) will be different. In furtherance of the comparison,
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one can utilize the earlier discussed deviance goodness-of-fit test (McCullagh and
Nelder, 1989), where (3.14) is the full (or saturated) model and (3.13) is the re-
duced model. We note that Qˆ(xit) is used in (3.12) as a known function, thus the
calculated penalty-reward scores will still be conditionally independent on Qˆ(xit)
for both clinical procedures.
In the event that the type I error rate for the test is marginally different from
the initial nominal level, it is possible that through some statistical adjustment
to the significance level or p-value, we will be able to ensure that they will be
compatible. For such technicalities, these are outside the scope of this paper.
Similarly, addressing the concerns in the usage of the linear regression when it is
performed on an unbalanced data set, Littell et al. (2002) stated the usefulness
for unbalanced data as this method does not generally require balanced datasets.
SECTION 3. NUMERICAL EXAMPLES
To illustrate our proposed test procedures, as well as the proposed algorithm
to estimate p(xt), an illustration of two examples using real data is shown. The
proposed algorithm to estimate p(xt) is employed to visualize the form of the odds
ratio and to give an illustration of the effectiveness of the clinical procedures or
physicians’ performance in each example. Our proposed test procedures and the
McNemar’s test are employed to detect any differences in performance in one of
the examples and their corresponding results are presented.
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Section 3.1 First Example: Acute Myocardial Infarction Admission
in a Hospital
The first example utilizes data on the outcomes of patients with an acute
myocardial infarction (more commonly known as heart attack) who are admitted
to an anonymous hospital, collected as part of the NHS Research and Development
funded EMMACE-1 (Evaluation of Methods and Management of Acute Coronary
Events) Study (Dorsch et al. 2000). The post-operative outcomes after thirty days
were collected for these patients admitted over a 3-month period. The mortality
risk for each patient was both calculated and authenticated locally at the hospital.
A total of 123 patients were observed and a cognizance of 27 deaths resulted in a
mortality rate of 21.95%.
Since the mortality risk xt is between 0 and 1 and from the previous studies of
the mortality risk distribution, its theoretical model distribution may be modeled
using a beta distribution. Quantile-quantile plots was then used to estimate the
parameters among the probable location-scale family of beta distributions and the
model distribution for the data set was parameterized by shape parameters α = 1
and β = 3.
Supplementary to the discussion earlier, a scatter plot of the data (xt, yt)
will not be too informative. We are still able to note some characteristics of the
data, namingly that the mortality rate appears to increase with the mortality risk
and that the probable model distribution of the mortality risk, xt is a decreasing
probability distribution where smaller mortality risk values are more probable. To
obtain more revelatory features of the data, we obtained a plot of the estimated
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mortality rate pˆ(xt) against the mortality risk xt, using kernel-based matching es-
timators in (3.4), in Figure 3.2. Subsequently, we can also transform the estimated
mortality rate pˆ(xt) to map the odds ratio against the mortality risk xt to obtain
a more informative chart of the odds ratio function, as shown in Figure 3.2. From
this plot in Figure 3.2, we observed that a horizontal line fit may be adequate as
the points are randomly scattered around a horizontal line, showing no relation-
ship between odds ratio and mortality risk, an indication that the effect of the
true performance of the hospital might be the same (on the odds ratio) regardless
of the mortality risk. In order to smoothen the estimates pˆ(xt), we apply the MSE
criterion in (3.6) to find an estimate of the odds ratio Q and we obtain Qˆ = 0.72.
Since Qˆ < 1, this suggests that there is possibly a decrease in the mortality rate
across all levels of mortality risks. All in all, it supports the findings in Johnson
et al. (2005) that the hospital exhibits “consistently good performance”. Though
Johnson et al. (2005) also found that there is a possible sudden downturn in the
hospital’s performance, our proposed method will consider all the available data
as a whole, thus the deterioration in performance might be “averaged” (offset) by
the other performances of the hospital. It is important for both clinicians and
governance boards that our proposed method is not a monitoring tool but it is
to obtain an overview of the average performance of the hospital accounting for
the mortality risk xt. It is more fundamental to reflect the overall quality of med-
ical practice than to seek a possible occurrence of an isolated situation. We are
not implying that such isolated situations should be neglected. They should still
be identified for further investigations to reduce the variability in the quality of
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medical practice and plausible causes for such situations.
Section 3.2 Second Example: Cardiac Surgery Operations in a Hospital
Our next example is exemplified with data from an anonymous hospital in
UK. For this data set, the patients underwent cardiac surgery operations in the
hospital and their post-operative outcomes after thirty days were collected. The
given corresponding mortality risk xt for each patient was both calculated and
authenticated locally at the hospital. Due to confidentiality and anonymity of the
data, only a subset of the data is in our illustration. A total of 426 patients over
a period of time are considered and the data is stratified based on two physicians,
with the first 322 patients being treated by a trainee physician, and the remaining
104 patients being treated by an experienced physician. The resulted unadjusted
mortality rates of 2.80% and 3.85% are observed respectively, thus showing that
the trainee physician is probably performing better than the experienced physician.
However the standardized mortality ratio (SMR) for both surgeons are recorded as
0.952 and 0.683. This statistic is the ratio of observed mortality rate to predicted
mortality rate. In our example, it indicates contradicting conclusions that the
trainee physician is actually performing worse than the experienced physician.
This suggests that adjustment for the patient mix is critical. In fact, from further
examination of the data, it is found that the patient mix for both physicians are
different, with the experienced physician treating patients of higher mortality risk.
Upon using the kernel-based matching estimators in (3.4), by pooling patients
treated by both physicians, the plot of odds ratio against the mortality risk xt in
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Figure 3.3 seems to indicate that the odds ratio might not be the same across all
levels of mortality risks, but instead it is more likely to be a linear function of the
mortality risk xt. As such, we apply the MSE criterion in (3.6) with Qˆ = axt+b to
find an estimate of the odds ratio Q function. We then obtain the plot of mortality
rate pˆ(xt) against mortality risk xt after smoothing for both physicians in Figure
3.3. Indeed it suggests that the trainee physician may be performing better than
the experienced physician for patients of extremely low mortality risk (mortality
risk below 0.0316) for the probable reason that the experienced physician might
have taken over the operations for such patients if there are implications. This
also account for a low number of such patients seen by the experienced physician.
It can also be noted that the performance of the experienced physician is generally
better than that of the trainee physician for patients across other levels of mortality
risks (mortality risks between 0.0316 and 0.139). It is not meaningful to compare
the performance of both physicians for patients of mortality risks above 0.139 as
the trainee physician did not operate on such patients.
Subsequently, we conduct tests to evaluate the performance between the two
physicians. The McNemar’s test results in a p-value of approximately 1, upon
the pairing of patients with the same mortality risk for both physicians. This
additional step of pairing is not only troublesome, it is also cost-ineffective as
we obtain only 94 pairs of patients as a result. This imply that 228 and 10
patients are left out in this analysis for the trainee physician and experienced
physician respectively. There are also only 6 discordant pairs, which indicates
that 88 concordant pairs are not utilized using the McNemar’s test, thus possibly
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losing valuable information from the data.
The implementation of the risk-adjusted test procedures proposed in the ear-
lier Section yield both p-values of approximately 0 if we implemented the test
procedures formulated using SPRT, based on the models discussed in (3.13) and
(3.14), as well as that formulated using logistic regression, based on the logistic
models discussed in (3.9) and (3.10). With our proposed method, we are also able
to identify the extent of the differences in their performances for different values
of the mortality risks, as shown in Figure 3.3 and it does suggest that the per-
formance of the experienced physician is generally better than that of the trainee
physician for patients across most levels of mortality risks (mortality risks between
0.0316 and 0.139).
It is important to note that the implementation of the proposed risk-adjusted
test procedures are able to indicate probable differences in the performances of
the physicians, controlling for all possible risk-adjusting factors mentioned above.
Only upon seeking out these probable differences, there can begin a process to
improve the performances, which may include retraining of staff or upgrading of
equipment. For such technicalities, these are outside the scope of this paper.
SECTION 4. SIMULATION STUDY TO COMPARE
MCNEMAR’S TEST AND PROPOSED METHODS
To further investigate the efficiency of our proposed test procedure, a sim-
ulation study was conducted. A comparison of our proposed procedure and the
McNemar’s test will be analyzed and their corresponding efficiencies will be pre-
sented. The focus of the comparison is on the following factors: size of the dif-
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ference in parameters being tested for, the distribution of the mortality risk xt
and the odds ratio function assumed. The basis for determining the parameters
and various aspects of the simulation study will be by simulating a data set with
distributional characteristics which mimics that of the real data set in the first
example, which we had discussed earlier in Section 3. This will ensure that our
simulation studies are befitting of real-life scenarios.
Section 4.1 First Simulation Study: Under Constant Odds Ratio
The first part of our simulation study was to show the performance of our
proposed procedure, as compared to the McNemar’s test. The hypothesis of inter-
est will be analogous to that for Steiner’s risk-adjusted CUSUM, in which primary
interest is with regards to the constant odds ratio of the mortality of a patient.
To compare the performance of two clinical procedures, we will be testing this
constant odds ratio, where H0 : Q1 = Q2 versus HA : Q1 6= Q2, where Qi is the
odds ratio of the mortality of a patient under Procedure i (i = 1, 2). This is
equivalent to testing H0 : ∆Q = 0 versus HA : ∆Q 6= 0 where ∆Q = Q1 − Q2 is
the difference in the odds ratio between the two clinical procedures. Based on the
earlier data set, we will specify Q1 = 0.72 as found in Section 3.
For each value of ∆Q considered in this study, the simulation was repli-
cated 10000 times, resulting in 10000 data sets. Each data set comprised data
for n = 2000 patients, with 1000 patients treated using Procedures 1 and 2 respec-
tively. The mortality risk xit for each patient was drawn from a beta distribution
with shape parameters α = 1 and β = 3, and the corresponding discrete outcome
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generated from a Bernoulli distribution with pi = Qixit/(1− xit +Qixit) where
Q1 = 0.72 and Q2 = 0.72 + ∆Q. The data will be analyzed to compare if the
performance of the two clinical procedures are different. It is important to note
that the McNemar’s test will require an additional step before this can be imple-
mented. In our study, the pairing of patients between Procedures 1 and 2 will be
accomplished using a rule that will invoke the principle of optimal distance. This
implies that the patients treated upon using each clinical procedure are matched
based on their mortality risks and patients with the closest mortality risk for Pro-
cedures 1 and 2 are matched, with no patients (100% matching), 200 patients each
(80% matching), 500 patients each (50% matching) and 800 patients each (20%
matching) being left out in each matching procedure. This will adequately address
a practical limitation of using the McNemar’s test in which valuable information
is possibly lost through the use of matched pairs, where some patients might not
be taken into account. For example, in Chen, Connors and Garland (2008), due
to a matching percentage of only 20%, information from the remaining 80% of the
initially observed patients was not taken into account.
Our proposed test procedure will also be executed by using the test procedures
formulated from SPRT on the models discussed in (3.13) and (3.14), as well as on
the logistic models discussed in (3.7) and (3.8). In order to identify the importance
of using the correct model of the relationship between logit[p(xt)] and xt, we also
performed the test on the logistic models discussed in (3.1) and (3.2).
Each procedure for testing will be carried out based on a test of the relevant
null hypothesis at the 5% and 1% significance level, with the empirical power being
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defined as the proportion of each 10 000 data sets in which the null hypothesis H0
was rejected by the corresponding test.
First we examine the empirical type I error rates for the four tests in Table 3.1
and we see that our three tests and the McNemar’s test have empirical type I error
rates which are compatible with the nominal 5% and 1% (not shown here because
similar conclusion is obtained) levels, with error rates for our tests minimally
lower than the nominal levels and that for the McNemar’s test (with matching
percentage of 100%) marginally higher. We conclude that for the purpose of
comparing two clinical procedures, all tests appear reasonable under the simulation
settings considered here. As the matching percentage for the McNemar’s test
decreases, the empirical type I error rates are also observed to be decreasing.
Examining the empirical power of the tests, in broad terms, the performance
between the McNemar’s test (with matching percentage of 100%) and the test
comparing the incorrect pair of models (3.1) and (3.2) is similar. The test proce-
dures formulated from SPRT on the pair of models (3.13) and (3.14), as well as
on the logistic models discussed in (3.7) and (3.8) also show similar performance.
These findings are consistent when the tests are performed at both 5% and 1%
significance level. Some of these findings are shown in Table 3.1. Though McNe-
mar’s test has performed adequately, it is important to note that the experimental
setting required for this test is also more troublesome and less cost effective. As
the McNemar’s test requires patients from both clinical procedures to be matched,
information is lost as there are patients not taken into account due to the match-
ing procedure. This results in a loss in power of the McNemar’s test, as shown
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in Table 3.1. As the matching percentage decreases, the empirical power of the
McNemar’s test also decreases significantly.
Our proposed test procedures will not meet this drawback as it does not
require that the patients to be matched, thus it is much more cost effective, with no
compromise in the power of the test. Moreover, by looking at the empirical power
of the tests comparing (3.7) and (3.8), and that comparing (3.1) and (3.2), we
observe that the power of the test is diminished due to the incorrect specification
of the logistic model, thus showing the importance of the introduction of the
independent variable logit(xit) in the logistic models.
We then repeat the above simulation study by changing the setting such
that each data set comprised data for n = 2000, 1000, 500 and 200 patients,
with 1000, 500, 250 and 100 patients treated using both Procedures 1 and 2
correspondingly. The data will be analyzed to compare if the performance of the
two clinical procedures are different again.
First we examine the empirical type I error rates for the three tests in Table
3.2 and we see that our two tests and the McNemar’s test have empirical type I
error rates which are compatible with the nominal 5% level, with error rates for
our tests minimally lower than the nominal levels and that for the McNemar’s test
(with matching percentage of 100%) marginally higher. We conclude that for the
purpose of comparing two clinical procedures, all tests appear reasonable under
the simulation settings considered here. We also notice that as the sample size for
each data set decreases, the empirical type I error rates are also observed to be
increasing.
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Examining the empirical power of the tests, in broad terms, the performance
between the McNemar’s test and our two proposed tests is different, with the
McNemar’s test showing less power and both our tests showing similar but higher
power as compared to the McNemar’s test. These findings are shown in Table 3.2.
Similarly, we also noticed that as the sample size for each data set decreases, the
empirical power of the tests decreases significantly. This illustrate that all the
tests are dependent on the sample size, similar to most test procedures.
Section 4.2 Second Simulation Study: Under Variable Degree
in Performance Differences across Mortality Risks
In the second part of our simulation study, it is designed to investigate prob-
able limitations in using the McNemar’s test. The primary interest is the same as
before, which is also to compare the performance of two clinical procedures, but
the odds ratio is not taken to be identical (constant) across all levels of mortality
risk xt. Instead it is taken to be a linear function of the mortality risk xt. The
non-constant odds ratio is valid, as it is possible that the effect of the performance
of the clinical procedure is different across the range of mortality risk xt as shown
by our second example, which we had discussed earlier in Section 3. The simu-
lation process is similar to that conducted in the earlier experiment, but instead
of constant Q we will specify Q1(xt) = 0.30 and Q2(xt) = α + βxt, listed in Ta-
ble 3.3. Similarly, once the data set is obtained, it will be analyzed to compare
the performance of the two clinical procedures by implementing the proposed test
procedures, with the exception that instead of comparing (3.7) and (3.8), we will
compare (3.9) and (3.10). The plots of the mortality rate p(xt) against the mortal-
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ity risk xt for the different odds ratio function Q2(xt) considered in our simulation
settings are also given in Figure 3.4.
Upon the examination of the empirical type I error rates for the four tests
in Table 3.3, we observe that all tests have empirical type I error rates which are
compatible with the nominal 5% level. The four tests appear to be appropriate for
the comparison of two clinical procedures. However, through the examination of
the empirical power of the tests, all the tests differ substantially in performance.
Firstly if the effect between the performances of the two clinical procedures differs
across the range of mortality risks, such as one procedure performing better for
patients of lower mortality risks but worse for patients of higher mortality risks,
the power of the McNemar’s test will be greatly undermined. This is particularly
so when the clinical procedures’ plot of mortality rate, p(xt) against the mortality
risk xt intersect, as shown in Figure 3.4. The power of the McNemar’s test can be
significantly lower than that of our proposed test procedures. The primary reason
is due to the cancellation of the effects between the performances of the two clinical
procedures, since one procedure performs better than the other across a range of
mortality risks but tend to perform worse over the other range of mortality risks.
This scenario is befitting of real-life situations. For example in the treatment of
coronary heart disease, coronary angioplasty is recommended for patients of lower
risk and might not be as effective for patients of higher risk, while CABG surgery
is conducted on patients of higher risk and might not be as effective for patients
of lower risk. By looking at the empirical power of the tests comparing (3.9) and
(3.10), and that comparing (3.1) and (3.2), we again observe that the power of the
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test is diminished due to the incorrect specification of logistic model, thus showing
the importance of the introduction of the independent variable logit(xit) in the
logistic models.
In summary, on top of the drawbacks of high costs of implementation, the
McNemar’s test is not able to identify the point of intersection in the clinical
procedures’ plot of mortality rate against mortality risk, since upon pairing of the
patients, information of the patients’ mortality risks are “lost”. Using the proposed
algorithm to estimate p(xt), we are able to obtain a more informative plot of
mortality rate pˆ(xt) against mortality risk xt after smoothing for each clinical
procedure, thus identifying the probable point of intersection or the change in the
effects between the performances of the clinical procedures. The proposed test
procedures can also be implemented to test for the comparison of the two clinical
procedures, while accounting for possible varying degree of the differences between
the performances of the two clinical procedures across the range of mortality risks.
Section 4.3 Third Simulation Study: Under changes in the
Underlying Mortality Risk Distribution
Rogers et al. (2004) have voiced their concerns about the effect of changes in
the underlying mortality risk distribution on the performance of the risk-adjusted
CUSUM chart. In our first example, the mortality risk distribution was modeled
using a beta(1,3) distribution but this is not always the case. For clinical pro-
cedures, such as CABG surgery, they are performed on patients of higher risk.
This will in turn result in a mortality risk distribution that is more skewed to the
right, with more patients with higher risks. For other procedures, such as coro-
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nary angioplasty which is recommended for patients of lower risk, the mortality
risk distribution will be less skewed to the right, with more patients with lower
risks. As such, this part of our simulation study is designed to investigate the sen-
sitivity of our proposed test procedures to changes in the underlying mortality risk
distribution for the two clinical procedures. Here the simulation process is similar
to that conducted in the first experiment but the mortality risk for each patient
for both procedures was drawn from a beta distribution with shape parameters
α = 1 but with different values of β. Once the data set is obtained, it will be
analyzed to compare the performance of Procedures 1 and 2 by implementing the
test procedures on models discussed in (3.13) and (3.14), as well as on the logistic
models discussed in (3.7) and (3.8).
Similarly, we examine the empirical type I error rates for our proposed test
procedures in Table 3.4 at nominal 5% level, we observe that the empirical type
I error rates decrease as the distribution becomes less skewed to the right. This
is due to the reason that as the distribution becomes less skewed to the right,
the mortality risks of the patients become more concentrated at the lower risk
values. As a result, the differences between the two procedures will be estimated
more accurately around these risk values, thus leading to less evidence of any
differences between the two procedures.
We conclude that as the distribution becomes less skewed to the right (when
β increases), the tests become more conservative (that is, less likely to reject H0
whether true or false). In contrast, as the distribution becomes more skewed to
the right (such as when β decreases), the tests become more liberal (that is, more
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likely to reject H0 whether true or false).
In summary, the degree of conservativeness of the test, and therefore its va-
lidity and the conclusions drawn from the tests have to be treated with caution
as well. It is possible that through some statistical adjustment to the significance
level, we will be able to ensure that the type I error rates will be compatible to
the initial nominal level.
SECTION 5. CONCLUSION
At present, risk-adjusted analytical tools are best used as a screening or mon-
itoring procedure (Cook et al. 2008), rather than to compare the performances of
clinical procedures. To compare performances of clinical procedures, it is common
to obtain two groups of patients who were treated by either clinical procedures and
their pre-operative mortality risks are matched. This ensures that the matched
pairs are well-balanced with respect to all potentially confounding variables. Af-
terwhich, the McNemar’s test is used to assess the difference between the two
procedures. The McNemar’s test has the advantage of being robust against the
underlying mortality risk distribution as it has accounted for the risk distribution
through the matching procedure. Due to the earlier mentioned, the McNemar’s
test will also not be able to show the exact performance of each clinical procedure
as it is only able to establish differences between the two correlated proportions. It
is also noted that the implementation of the McNemar’s test becomes more trou-
blesome and less cost effective as this might result in excessive loss in information
because there might be many patients that are not paired and thus not taken
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into account. This results in possibly significant loss in power of the McNemar’s
test, as shown in our simulation study. The McNemar’s test also focuses only on
the discordant pairs, thus possibly losing further valuable information from the
data. Through our simulation study, we also demonstrate that the McNemar’s
test is highly sensitive to the degree of the differences between the performances
of the two clinical procedures, for example if one is performing better for patients
of lower mortality risks but worse for patients of higher mortality risks. This is
because the McNemar’s test assumes that the degree of the differences between the
performances of the two clinical procedures are the same for any pair of patients.
It is noted from current literature, that in order to compare performances of
clinical procedures, it is common to compare logistic models which utilize a linear
function of the independent variable (mortality risk), using logistic regression. As
such, this method is dependent on the model used. If a wrong model is used,
this will in turn result in a less powerful test, as shown by our simulation studies.
However, unlike linear regression, there is no R2 associated with a logistic model,
thus it is not simple to evaluate whether a model is wrongly used. It is then of
importance that we develop a model-free technique to estimate the actual mortality
rates for all levels of predicted mortality risk. This proposed diagnostic technique
will allow us to evaluate the effectiveness of the clinical procedure by investigating
the mortality rates and resulting odds ratio function against the mortality risks.
More importantly, it does not assume any relationship between the mortality rates
and risks.
Using the estimated mortality rates obtained utilizing our diagnostic tech-
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nique, as well as using logistic regression, we present two sets of risk-adjusted test
procedures that can also be used to compare the clinical procedures’ performances,
or specifically compare if the odds ratio function of the mortality risk is the same
for both procedures. For the first set, we utilize the logistic regression to formulate
the procedures by introducing the independent variable logit(xit) in the logistic
models, while for the second set, we proposed the risk-adjusted penalty-reward
scores to reflect the pre-operative mortality risk and mortality outcome of each
patient. This alleviates the problem of interpretation since larger positive values
of Wt for one clinical procedure as compared to another clinical procedure can
be interpreted that the performances of the two clinical procedures are different.
It also provides an alternative test which is derived using the SPRT and inspired
from the classical likelihood ratio test. This approach provides an intuitive way to
average “evidence” over the patients, while adjusting for the case-mix of patient
characteristics that might significantly affect the mortality risk. Both proposed
test procedures also do not require that the patients to be matched, thus it is
much more cost effective.
Our proposed test procedures are also able to overcome the drawback of be-
ing sensitive to the degree of the differences between the performances of the two
clinical procedures, and are yet able to achieve good efficiency as compared to
when the McNemar’s test is used. It is important to note that similar to most
tests, the degree of conservativeness of our proposed tests, and therefore its valid-
ity and the conclusions drawn from the test procedures have to be treated with
caution. Finally, the last key advantage of our proposed test procedures is that
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through slight modifications, it can also be used to compare more than two clinical
performances.
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Table 3.1. Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3)
n Q1(xt) Q2(xt) McNemar’s test with matching percentage of Logistic Regression SPRT
Usual Correct
Models Models
100% 80% 50% 20% (3.1) vs (3.2) (3.7) vs (3.8) (3.13) vs (3.14)
1000 0.72 0.72 0.0591 0.0419 0.0404 0.0328 0.0453 0.0456 0.0454
0.72 0.30 0.9996 0.9990 0.9809 0.6164 1.0000 1.0000 1.0000
0.72 1.12 0.9399 0.9038 0.6757 0.2783 0.9330 0.9632 0.9621
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Table 3.2. Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3) for various n
n Q1(xt) Q2(xt) McNemar’s test Logistic Regression SPRT
(100% matching) Correct Models [(3.7) vs (3.8)] (3.13) vs (3.14)
1000 0.72 0.72 0.0591 0.0456 0.0454
0.72 0.3 0.9996 1.0000 1.0000
0.72 1.12 0.9399 0.9632 0.9621
500 0.72 0.72 0.0613 0.0478 0.0472
0.72 0.3 0.9648 0.9742 0.9703
0.72 1.12 0.8216 0.8354 0.8338
250 0.72 0.72 0.0641 0.0491 0.0488
0.72 0.3 0.8567 0.8930 0.8854
0.72 1.12 0.4298 0.4734 0.4701
100 0.72 0.72 0.0679 0.0519 0.0517
0.72 0.3 0.4931 0.5300 0.5269
0.72 1.12 0.2158 0.2321 0.2302
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Table 3.3. Empirical type I error and power at a 5% significance level under
H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt), with the distribution of the
mortality risk as beta(1,3) for true non-constant Q2
Q1(xt) Q2(xt) McNemar’s test Logistic Regression SPRT
Usual Models Correct Models
(3.1) vs (3.2) (3.9) vs (3.10) (3.13) vs (3.14)
0.3 0.3 0.0535 0.0446 0.0496 0.0495
0.3 0.2 + 0.5 xt 0.0708 0.3599 0.4960 0.4543
0.3 0.8 xt 0.5097 0.6431 0.7934 0.7638
Table 3.4. Empirical type I error rates of the test procedures for ∆Q = 0 cor-
responding to various underlying mortality risk distributions for both clinical
procedures under H0 : Q1(xt) = Q2(xt) versus H1 : Q1(xt) 6= Q2(xt)
Distribution Logistic Regression SPRT
(3.7) vs (3.8) (3.13) vs (3.14)
Beta(1, 2.0) 0.0521 0.0478
Beta(1, 2.5) 0.0491 0.0467
Beta(1, 3.0) 0.0456 0.0454
Beta(1, 4.0) 0.0449 0.0440
Beta(1, 5.0) 0.0437 0.0439
Beta(1, 10.0) 0.0413 0.0412
Beta(1, 20.0) 0.0392 0.0395
Beta(1, 50.0) 0.0370 0.0384
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Figure 3.1. Penalty-reward scoreWt awarded to a surgeon according to a patient’s
pre-operative risk xt, where H0 : p0(xt)/[1 − p0(xt)] = Q0xt/(1 − xt) versus
HA : pA(xt)/[1− pA(xt)] = QAxt/(1− xt).
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. . . . . . . . . . . . . . . . . . . . . . . . . .Qˆ = 0.72
Figure 3.2. Plot of mortality rate pˆ(xt) against mortality risk xt, and plot of odds
ratio of mortality Q against mortality risk xt after smoothing with patients with
an acute myocardial infarction who are admitted to an anonymous hospital,
collected as part of the EMMACE-1 Study. The dashed and dotted curves in
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Qˆ(xt) = 0.980− 2.121xt














































Figure 3.3. Plot of odds ratio of mortality Q against mortality risk xt after smooth-
ing and plot of mortality rate pˆ(xt) against mortality risk xt, for trainee physi-
cian and experienced physician after smoothing for patients who underwent
cardiac surgeries in an anonymous hospital in UK.
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Q2(xt) = 0.8 xt
Q2(xt) = 0.2 + 0.5 xt
Q1(xt) = Q2(xt) = 0.3
. . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
. . . . .
Figure 3.4. Plot of mortality rate p(xt) against mortality risk xt.
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CHAPTER 4: STANDARDIZED MORTALITY
RATIO (SMR): FACTS AND MYTHS.
A REVIEW ON THE USAGE OF SMRs
SUMMARY
The ability to assess medical practice is central to quality assurance. One
such widely-used overall quality indicator and measurement tool will be the stan-
dardized mortality ratio (SMR) by comparing the observed mortality rate to the
predicted rate. Despite being available for some time, health service providers are
still skeptical on its ability to truly identify poor-quality providers. Recent paper
has emphasized the validity of case mix adjustment methods used to predict the
mortality rates. Beyond this methodological bias, in this paper, we will investigate
various limitations of using the SMR by using worked examples and simulation
studies. We also provide theoretical estimates of the mean and variance for SMR.
The highlights of various possibly wrong interpretations through the use of SMR
are also adequately discussed.
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SECTION 1. INTRODUCTION
The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (Werner and Bradlow, 2006, Clarke
and Oakley, 2007, Krumholz et al., 2008, Biswas and Kalbfleisch, 2008, Steiner and
Jones, 2009). Measuring quality of care in medical practice is a key component in
improving efficiency in health care. The crux of monitoring clinical performances
can be attributed to distinguished names from earlier times, such as Florence
Nightingale, Ernest Codman and Lord Moynihan (Chambler and Emery, 1997,
Kaska and Weinstein, 1998, Spiegelhalter 1999). Such assessment is playing an
increasingly prominent role in quality management. For example, in 1999, an
independent body, the UK National Institute of Clinical Excellence was estab-
lished, after the UK General Medical Council found three doctors possibly guilty
of professional misconduct over the quality of their heart surgeries conducted.
The professional misconduct led to 29 mortalities out of 53 children who were
operated at the Bristol Royal Infirmary (2001, BBC News 1998). In 2006, a pro
tempore closure of the cardiac surgical department at the Radboud University
in the Netherlands was also initiated after an analysis of the mortality rates was
conducted. The reactions to these health care tragedies stress the importance of
clinical performance monitoring as timely signals of deteriorated performance can
be used to identify plausible causes and this will in turn avoid future avertible
mortalities or other adverse health issues.
In order to make clinical performance information readily accessible to the
public, payers and providers of care, the United States Centers for Medicare and
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Medicaid Services has been collaborating with various health care organizations
to participate in the Hospital Quality Alliance (2006). It is therefore crucial that
information released is reasonably accurate and fairly representative such that it
is of significant value. But the release of such performance report cards might
lead to misinterpretation of the data. Patients in hospitals tend to differ notably
in terms of pre-procedural risk of failure, which in this paper we will refer to as
mortality risk. If this variability in the mortality risk is not taken into account
when assessing a particular hospital’s performance, this variability might result
in additional fluctuation in the outcomes, thus masking the effect of the true
performance of the hospital, and resulting in misapprehension of the true situation.
For example, if a particular hospital has a relatively low mortality rate, it will give
an impression that this hospital is highly, and vice versa. As such, the New
York State Department of Health (2008) do not just publish raw mortality rates,
they also publish risk-adjusted mortality rates, which is an indication of what a
hospital’s mortality rate would have been, had she treated patients identical to
the state’s average.
Another one such widely-used overall quality indicator and measurement tool





Number of observed deaths
Predicted number of deaths
,
(4.1)
where the predicted mortality rate is calculated using a reference model, and this
statistic serves as an indirect method of adjusting for the risk. For a hospital,
a SMR value that is equal to 1 suggests that there is no difference between the
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observed mortality rate and the predicted mortality rate. However, a SMR value
greater or lesser to 1 suggests that the hospital’s mortality rate is higher or lower
than the predicted mortality rate respectively, thus also indicating whether the
performance is good or poor respectively. This statistic has been available and
been publicly released for some time and it is usually recommended to be viewed
in context with other quality indicators. The SMR is used only as a tool to
help health service providers identify the trends in their hospital mortality rate
and make quality improvements based on the results. This practice has been im-
plemented in various countries such as the United States, the United Kingdom,
Sweden and Holland. For example, by tracking SMR and implementing a range
of improvements as a result of what is learnt, the Walsall hospital in the United
Kingdom was able to reduce mortality by 40% in only 4 years. Despite its use-
fulness, health service providers are still skeptical on its ability to truly identify
poor-quality providers and they doubt its validity to be used as a measure for
comparing providers publicly (Consortium of Chief Quality Officers, 2009).
In the literature to compare health care providers, there has always been con-
cerns on the non-standardized documentation and coding of patients’ conditions,
as well as on the validity of case mix adjustment methods used to predict mortality
rates. Beyond this methodological bias, on the other hand, Rogers et al. (2004)
expressed their concerns about the effect of changes in the underlying mortality
risk distribution on the performance of the risk-adjusted CUSUM chart. We are
motivated to investigate the effectiveness of using SMR to compare hospitals when
their corresponding mortality risk distributions are different. We demonstrate this
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using a real data set. For this data set, the patients underwent cardiac surgery
operations in an anonymous hospital in UK and their post-operative outcomes
after thirty days were collected. The corresponding mortality risk for each patient
was both calculated and authenticated locally at the hospital. The data is strat-
ified based on 3 physicians, which we will identify them as Physicians A, B and
C. We calculate the SMR values for Physicians A, B and C to be 0.6780, 0.8112
and 0.9318 respectively. This leads to a suspectible conclusion that the physicians
differ in their performances, with Physician A showing the best performance and
Physician C showing the worst performance amongst the three. Could this con-
jecture be flawed due to other reasons? Investigating the average mortality risk of
patients seen by each physician, that for Physicians A, B and C are found to be
0.0309, 0.0439 and 0.0478, with Physician A operating on more patients of lower
risks and Physician C operating on more patients of higher risk. A physician who
operates on patients of lower risks should show better performance than another
who operates on patients of higher risks by having a lower mortality rate. As such,
the discrepancies in SMR values are possibly due to differences in the mortality
risk distributions. In fact, using an alternative statistics in (4.6) proposed in Sec-
tion 3, the performances between the 3 physicians are found to be similar with
Q˜ = 0.5984, 0.6008 and 0.6014.
In order to better understand the validity of using SMR to compare hospitals,
in Section 2, we will provide a review of literature discussing various limitations
of using SMR, as well as highlight various possibly wrong interpretations through
the use of SMR. Theoretical estimates of the mean and variance of SMR are also
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provided. An alternative statistic for the comparison of hospitals will be proposed
in Section 3. Using real applications in health care context, the comparison of
using the proposed method and SMR will be analyzed and the findings presented
in Section 4. The conclusions and important findings will then be highlighted in
the last section.
SECTION 2. FACTS AND MYTHS OF SMR
Section 2.1 Literature Review of Using SMR
There have been controversies in the inferences drawn from a wide variation in
hospitals’ SMR published publicly. However, these published SMR portray diver-
sities in quality of care. In the 2007 hospital guide for UK, Dr Foster Intelligence
depicted SMR as “an effective way to measure and compare clinical performance,
safety and quality.” But it has been noted that SMR requires the predicted mor-
tality rate to be calculated and this is done using some reference model obtained
from some developmental data set. Jones, Redmond and Templeton (1995) sug-
gested that the mortality prediction models can be applied to a new data set only
if the mortality risk distribution for the new data set is not statistically different
from that of the developmental data set. We note that since the predicted mor-
tality rate in SMR is calculated using some reference model, we emphasize that
SMR is a comparison of the index data set with the developmental data set. As
such, if the data tend to differ between each health care provider, the comparison
tends to be undermined, especially if comparisons are done across large numbers
of providers since it is unlikely that the data is similar.
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Lilford et al. (2004), Iezzoni (1997) and Mohammed et al. (2009) assessed
the validity of various case mix adjustment methods used to obtain the predicted
mortality rate and identified the importance of using the correct underlying case
mix adjustment method before any inferences on the comparison of health care
providers can be made. Much literature focus on limitations of current case mix
adjustment methods (Moore et al. 2010) due to inadequate risk adjustment and
non-standardization of documentation and coding in administrative data. In the
commentary released (Consortium of Chief Quality Officers, 2009), it was high-
lighted that when health care providers review the medical records of patients
among those whose mortality is “higher than expected”, the findings usually in-
clude finding very sick patients whose “expected” death rate is under-estimated.
However, amidst the above discussed disadvantages of using SMR, there are still
evident advantages in its usage, such as age-specific numbers of deaths are not
required in its calculation and its robustness to violations of the assumption of
proportionality. As such, Jarman et al. (2010) still promotes SMR as a powerful
tool to assess quality of care in Holland.
In the literature to compare health care providers, there has always been con-
cerns on the non-standardized documentation and coding of patients’ conditions,
as well as on the validity of case mix adjustment methods used to predict mor-
tality rates. Beyond the above discussed methodological bias, suppose that the
concerns on the non-standardized documentation and coding of patients’ condi-
tions are addressed, as well as the case mix adjustment methods used to predict
mortality rates are correct, we are motivated to investigate the effectiveness of
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using SMR to compare hospitals. Does that indicate that the use of SMR should
be encouraged amidst the absence of this methodological bias? We will first derive
theoretical estimates of the mean and variance of SMR.
Section 2.2 Theoretical Estimates of Mean and Variance of SMR
with Discussion on Limitations of Using SMR
Suppose we let y to be the post-procedural outcome for a patient, it corre-
sponds to one of two possible outcomes (success or failure). We assume yt is the
outcome for patient t. (1 if there is a mortality or 0 if a patient survives after
implementation of the clinical procedure). Notice that the outcome of the clinical
procedure may not be observed immediately after its implementation, with one
example being that for cardiac operations in which the outcome of mortality is
usually determined within 30 days from surgery. If patient t dies anytime within
30 days from the surgery, yt will be assigned a value of 1 and if the patient survives
after 30 days from surgery, yt will be assigned a value of 0. As a result, we have
the following probability function of yt, f(yt|p) = pyt [1 − p]1−yt , where p is the
mortality rate.
We further assume xt to be the mortality risk for patient t and it is estimated
prior to the implementation of the clinical procedure and it depends on the risk
factors present for the patient. This risk can be determined by using a rating
method, such as Parsonnet risk factors (Parsonnet, Dean and Bernstein, 1989) for
cardiac operations. Afterwhich, a logistic regression model is used to convert these
scores obtained from the rating method, to a risk value between 0 and 1. The risk
may also be computed based on a logistic regression model fitted to sample data
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or past data set, such as the EuroSCORE (Nashef et al., 1999) which is used to
evaluate the risk of patients for cardiac operations.
Since the mortality risk xt is between 0 and 1, and from previous studies of
the mortality risk distribution, its theoretical model distribution may be modeled
as beta(α,β). Morgan and Henrion (1990) and Moitra (1990) pointed out that the
use of beta distributions in modeling data in the form of proportions is due to its
large variety of shapes. Moreover, Hakes and Viscusi (1997) also discussed that
since the beta distribution is flexible and can assume a vast variety of skewed and
symmetric shapes, its use is not notably restrictive. As such, by assuming that the
risk distribution is modeled as beta(α,β), the theoretical estimates of the mean
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where Q is the odds ratio of the mortality of a patient and n is the sample size.
If Q = 1, this indicates that the estimated risk xt is the same as the mortality
rate p(xt) for all xt. We note that xt is based on the current conditions before
taking into account the effect of the true performance of the hospital. As such,
there is no difference in the performance of the hospital before and after taking
into account the effect of the true performance of the hospital. As Q increases, the
mortality rate increases, thus showing that there is a deterioration in performance.
If one hospital has a smaller Q than another hospital, it indicates that the former
hospital is performing better and vice versa.
The theoretical estimates of the mean and variance of SMR is compared
with that obtained from simulation studies and they are found to be compatible
(not shown here because similar conclusions are obtained). From the theoretical
estimate of V ar(SMR), we also observe that as n→∞, V ar(SMR)→ 0. Cook et
al. (2008) also highlighted that a confidence interval should always be included to
illustrate the precision of the SMR estimate. Upon obtaining theoretical estimates
of the mean and variance of SMR, we can obtain a confidence interval for the SMR
estimate. For such technicalities, these are outside the scope of this paper.
Using the theoretical estimates of the mean for SMR, we will discuss be-
yond the earlier discussed methodological bias, the effectiveness and limitations
of using SMR to compare hospitals when their corresponding mortality risk dis-
tributions are different. Though it has been discussed that SMR should not be
used to compare institutions with different patient case mix (Julious, Nicholl and
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George, 2001, Breslow and Day, 1987, Glance, Osler and Shinozaki 2000), these
discussions were based on simulation studies and real examples. In Glance, Osler
and Shinozaki (2000), they presented that SMR will decrease in a linear fash-
ion as the average mortality risk increases. However, we will like to highlight out
some important points in their simulation study. Firstly, from their analysis, SMR
should decrease in a quadratic fashion as the average mortality risk increases, as
the quadratic model will offer a better fit. Secondly, this relationship of SMR
decreasing with the increase in the average mortality risk is not necessarily true.
It depends on how the patient case mix is selected from their original data set, in
which across the 10 deciles of risk, the odds ratios, or more generally the perfor-
mance of the institution is not the same.
In this paper, we will present a more complete and theoretical approach to
this investigation.
Firstly, past literature has shown that the average mortality risk of patients
undergoing cardiac surgery has been predominantly increasing over the years. Par-
sonnet, Bernstein and Gera (1996) demonstrated that when the Parsonnet model
was applied to the patients of the Beth Israel Hospital in Newark, the average mor-
tality risk of patients had progressively increased by 47.7% in 1994, as compared to
that of 6.5 in 1988. The National Adult Cardiac Surgical Database Report (2001)
also showed similar trends when the average mortality risk of patients in 1999 had
increased by 20% over 3 years. Since much literature has placed great emphasis
on the average mortality risk, we will conduct the discussion, referring differences
in the risk distribution to differences in the average mortality risk.
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The risk distribution will be modeled by the beta distribution with shape
parameters α = 1 but with different values β, resulting in average mortality risks
of α/(α+β) = 1/(1+β), with n = 1000. We will also consider various values of the
odds ratio where Q = 1/2, 2/3, 1, 1.5 and 2, which are some values of proposed
odds ratio of interest (Steiner et al. 2000, Novick et al. 2006, Matheny, Ohno-
Machado and Resnic 2007). The plot of E(SMR) against the average mortality
risk for these values of odds ratio is shown in Figure 4.1.
Firstly, we observe that if the odds ratio Q = 1, regardless of whether the
mortality risk distributions are different, E(SMR) is always equal to 1. It is robust
to differences in the risk distribution.
However, for Q = 1/2, 2/3, 1.5 and 2, E(SMR) is affected by differences in
the risk distribution. Specifically, if Q > 1, E(SMR) decreases towards 1 as the
average risk increases, and E(SMR) is always above 1, but if Q < 1, E(SMR)
increases towards 1 as the average risk increases, and E(SMR) is always below 1.
This indicates that if one hospital has a SMR value greater than 1 while another
has that smaller than 1, we can compare these two hospitals and conclude that
the latter is performing better than the former.
However, if both hospitals have SMR values greater than 1 or smaller than
1, we are not able to compare these two hospitals without looking at the risk
distribution. This can be seen from Figure 4.1. For example, we see that the
E(SMR) values for Q = 2 at higher average risks, are smaller than that for
Q = 1.5 at smaller average risks. This might lead us to conclude that the former is
performing better than the latter based on the E(SMR) values. But we note that
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for the former, Q = 2 which is greater. As such, the earlier conclusion obtained
will be erroneous. This is also similar when Q < 1 in which the E(SMR) values
for Q = 1/2 at higher average risks, are higher than that for Q = 2/3 at smaller
average risks. This might again lead us to conclude that the former is performing
worse than the latter based on the E(SMR) values. But we note that for the
former, Q = 1/2 which is smaller, thus it is supposed to be performing better. As
such, a contradiction is reached with the earlier conclusion to be incorrect.
It has discussed that if the average mortality risk increases, SMR values are
expected to drop due to the decrease in the predicted number of deaths. However,
we will like to highlight that the observed number of deaths will also be in turn
affected. In conclusion, the E(SMR) values do depend on both the true underlying
performances of the hospitals and the mortality risk distribution of the patients
seen at each hospital, as seen from our theoretical study here.
Section 2.3 Possibly Wrong Interpretations through
the use of SMR
Upon identifying various limitations of using SMR, as well as that SMR de-
pend on both the true underlying performance and the case mix of patients, we
will highlight some possibly wrong and proper interpretations through the use of
SMR in the literature.
Amin et al. (2006) studied the roots of mortality after diagnosis of hepatitis
B or hepatitis C infections through the use of a large community-based study. It
was subsequently found that for liver-related deaths, the SMR for hepatitis B,
hepatitis C, and hepatitis B and C co-infected patients were 12.2, 16.8 and 32.9.
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The conclusion that all 3 groups of patients had increased risk of liver-related
death compared with the standard population is correct. However, it was also
highlighted that the greatest excess occurs in people diagnosed with hepatitis B
and C co-infection. We note that despite having a highest SMR value for this
group of patients, information on the mortality risk distribution is not released.
As discussed earlier, if the average mortality risk for this group of patients is the
lowest, it is possible that this co-infection might not be “performing that badly”,
thus indicating that people diagnosed with co-infection might not have the highest
odds ratio of mortality.
Huber-Wagner et al. (2009) studied the effect of whole-body CT during trauma
resuscitation on survival through the use of a retrospective, multicentre study. Be-
cause of the use of a multicentre study, the data might differ between each centre,
thus the case mix adjustment model might not valid.
Looking at the findings, SMR based on the trauma and injury severity score
(TRISS) was 0.745 for patients given the whole-body CT while for those given
a non-whole-body CT, SMR was 1.023. Similar results were also obtained using
revised injury severity classification (RISC) score with the SMR for the former to
be 0.865 versus 1.034 for the latter. The conclusion was that the integration of
whole-body CT significantly increased the probability of survival in patients with
polytrauma. This conclusion is correct because we are comparing SMR, with one
below 1 and the other above 1. This is because in the earlier section, we conclude
that regardless of the average risk, if Q > 1, E(SMR) is always above 1, and if
Q < 1, E(SMR) is always below 1. This conclusion will not be valid if both SMR
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are above or below 1, even if one is higher than the other.
In 2009, there was a study to investigate the relationship between mortalities
and prognostic factors in anorexia nervosa (Papadopoulos et al 2009). Some con-
clusions are highlighted. Firstly, it was mentioned that the highest SMR of 650.0
was found among patients with anorexia nervosa, with the second highest SMR
of 18.9 was for psychoactive substance use. The direct comparison of the value
of SMR should not done especially since the mortality risk distribution in each
group of patients is not discussed. Moreover, it was further discussed that a very
high SMR was found for the first year after first hospitalisation for anorexia and
the SMR was still significantly high 20 years or more after the first hospitalisa-
tion. This notion of being significantly high should be highlighted that the basis
of comparison is with the general population.
Lastly, there was a discussion on the reduction in acute myocardial infarction
mortality in the United States from 1995 to 2006 (Krumholz et al. 2009). The
same case mix adjustment model was used across all the years. Past literature
has shown that the average mortality risk of patients undergoing cardiac surgery
has been predominantly increasing over the years. As such, the model might
have changed over the years. The mortality risk distribution will also have been
different with different profile of patients over the years, thus the calculated SMR
should not be compared.
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SECTION 3. GENERAL APPROACH FOR PROPOSED STATISTIC
Monitoring of the effectiveness of clinical procedures and physicians’ perfor-
mance has been popularized well over 40 years ago in the medical field (Armitage,
1954 and Bartholomay, 1957). For the health care delivery, patients in hospitals
will differ notably in terms of mortality risk. An adjustment for prior risk has to
be implemented to ensure that the effect of the true performance of the clinical
procedure is not masked by the variability in this prior risk.
Steiner et al. (2000) then proposed the use of a risk-adjusted cumulative sum
(CUSUM) chart that accounts for the patient’s mortality risk. This risk-adjusted
CUSUM chart is formulated based on testing the odds ratio of the mortality of
a patient, where H0 : odds ratio = Q0 versus HA : odds ratio = QA. This
is equivalent to testing H0 : p0(xt)/[1 − p0(xt)] = Q0xt/(1 − xt) versus HA :
pA(xt)/[1− pA(xt)] = QAxt/(1− xt) with xt being the mortality risk for patient
t and the mortality rates p0(xt) and pA(xt) are functions of the mortality risk xt.
For a fixed value of xt, these mortality rates p0(xt) and pA(xt) are constants. In
essence, a statistic that can be used to compare hospitals could be formulated based
on the odds ratio. In order to obtain our proposed statistic, we will implement a
two-step procedure. We will first obtain a kernel-based matching estimator pˆ(xt;h)
to estimate p(xt). We then compute Qˆ(xt;h) for each xt, and obtain our proposed
statistic as the median of these computed values.
For the initial step, we will need to apply an algorithm that employs a “dis-
tance” threshold to estimate p(xt) for each xt. By using kernel-based matching
estimators which are commonly used in topological studies, we will form weighted
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where K(·) is the kernel function which is a probability density function that
is symmetric about the origin and integrates to 1 over the domain, and h is a
bandwidth parameter which controls the amount of smoothing of the data to
obtain the estimate. We have investigated various kernel function K(·) devel-
oped in the literature and the Gaussian kernel function with bandwidth h =
0.9n−1/5min{s, IQR/2.68} where IQR is the sample interquartile range and s
is the sample standard deviation, proposed by Chen and Kelton (2006) provides
satisfactory smoothing performance and emanates Qˆ adequately. Details can be
found in the Appendix of Chapter 3.
After we have estimated p(xt;h), we will then compute the estimated odds
ratio for each xt:
Qˆ(xt;h) =
pˆ(xt;h)(1− xt)
xt(1− pˆ(xt;h)) , (4.5)
and since the mortality risk distribution of patients is predominantly skewed, we
will obtain the proposed statistic as:
Q˜ = median{Qˆ(x1;h), Qˆ(x2;h), · · · , Qˆ(xn;h)}, (4.6)
Upon obtaining Q˜ for each hospital, the hospitals are ranked based on the values of
their corresponding Q˜, with the smaller values of Q˜ denoting better performances.
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SECTION 4. NUMERICAL EXAMPLES
To illustrate the procedure to use our proposed statistic, as well as to com-
pare the performance of this statistic and SMR, some illustrations of examples
using real data are shown and their corresponding results are presented. For the
first example, the patients underwent cardiac surgery operations in an anonymous
hospital in UK and their post-operative outcomes after thirty days were collected.
The corresponding mortality risk for each patient was both calculated and authen-
ticated locally at the hospital. The data is stratified based on 3 physicians, which
we will identify them as Physicians A, B and C. We calculate the SMR values
for Physicians A, B and C to be 1.3270, 1.2013 and 1.1932 respectively. This
leads to a conclusion that despite all 3 physicians exhibiting poor performance,
the physicians differ in their performances, with Physician C showing the best
performance and Physician A showing the worst performance amongst the three.
This conjecture could be flawed due to discussed reasons in Section 2.
By investigating the average mortality risk of patients seen by each physician,
that for Physicians A, B and C are found to be 0.0343, 0.0426 and 0.0445, with
Physician A operating on more patients of lower risks and Physician C operating
on more patients of higher risk. As such, the discrepancies in SMR values are
possibly due to differences in the mortality risk distributions. Using our proposed
statistics in (4.6), the performances between the 3 physicians are found to be
similar with Q˜ = 1.2473, 1.2433 and 1.2422.
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Similarly, for the second example, the patients underwent the same type of
surgical operations in another anonymous hospital in UK, and their post-operative
and mortality risk were collected. Likewise, the 3 physicians that conducted the
surgeries are identified as Physician A, B and C. The calculated SMR values are
1.3242, 1.2343 and 1.1862 respectively. Based on these SMR values, we might be
lead to conclude that all 3 physicians exhibit poor performance, with Physician C
showing the best performance and Physician A showing the worst performance.
However, the average mortality risk of patients seen by the 3 physicians are
0.0290, 0.0450 and 0.0462 respectively. As discussed earlier, the SMR values will
be affected by both the true underlying performances of the physicians and the
mortality risk distribution of the patients seen by each physician. Since all 3 SMR
values are above 1 and that the average mortality risk of patients seen by the
3 physicians are different, the conclusion drawn earlier might be incorrect. In
fact, using our proposed statistics in (4.6) with Q˜ = 1.1209, 1.2863 and 1.8188
respectively, we will reach a contradicting conclusion that Physician C actually
showed the worst performance while Physician A showed the best performance.
For our last example, we investigate the performances of 5 physicians (iden-
tified as A, B, C, D and E) in yet another hospital. The calculated SMR values
for the 5 physicians were 1.2220, 0.8273, 0.6833, 0.6300 and 0.4790 respectively.
With reference to the SMR values, we might conclude that all 5 physicians exhibit
good performance, with Physician E showing the best performance and Physician
A showing the worst performance.
90
However, the average mortality risk of patients seen by the 5 physicians were
0.0472, 0.0605, 0.0563, 0.0390 and 0.0271 respectively. Since the SMR values will
be affected by both the true underlying performances of the physicians and the
mortality risk distribution of the patients seen by each physician and that 4 of the
SMR values are below 1, with the average mortality risk of patients seen by those
4 physicians being different, the conclusion drawn earlier might be incorrect. The
only conclusion that we can reach safely will be that Physician A shows the worse
performance since it has an SMR of greater than 1. In fact, using our proposed
statistics in (4.6) with Q˜ = 1.3170, 0.2500, 0.5160 0.6371 and 0.8172 respectively,
we will reach the conclusion that the ranking of the Physicians with the best
performance to the worst performance should be Physician B, C, D, E and A.
SECTION 5. CONCLUSION
The evolution of the assessment of medical practice has been speeding up
tremendously, as seen from recent literature (Werner and Bradlow, 2006, Clarke
and Oakley, 2007, Krumholz et al., 2008, Biswas and Kalbfleisch, 2008, Steiner and
Jones, 2009). One such widely-used overall quality indicator and measurement tool
will be the SMR. The theoretical estimates of the mean and variance for SMR are
presented in this paper. In the literature to compare health care providers, there
has always been concerns on the non-standardized documentation and coding of
patients conditions, as well as on the validity of case mix adjustment methods
used to predict mortality rates.
Beyond this methodological bias, we observe that if the odds ratio Q = 1,
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regardless of whether the mortality risk distributions are different, E(SMR) is
always equal to 1. The SMR is robust to differences in the risk distribution. We
also observe that if one hospital has a SMR value greater than 1 while another
has that smaller than 1, we can compare these two hospitals and conclude that
the latter is performing better than the former. However, if both hospitals have
SMR values greater than 1 or smaller than 1, we are not able to compare these
two hospitals without looking at the risk distribution. Moveover, SMR depend
on both the true underlying performances of the hospitals and the mortality risk
distribution of the patients seen at each hospital, as seen from our theoretical
study.
Some possibly wrong and proper interpretations through the use of SMR in
the literature. An alternative statistic for the comparison of hospitals, formulated
based on the odds ratio, is proposed. To illustrate the procedure to use our
proposed statistic, as well as to compare the performance of this statistic and SMR,
some illustrations of examples using real data are shown and their corresponding
results are also presented.
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Figure 4.1. Plot of E(SMR) against average mortality risk, with the mortality risk
distribution as beta(1,β) and n = 1000.
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CHAPTER 5. CONCLUSION
We have proposed a joint monitoring scheme for clinical performance and the
mortality risk. We have demonstrated that this scheme is easy to implement and
is essential to avoid making erroneous inferences on clinical performance when the
mortality risk distribution has changed. A new charting procedure to monitor the
average mortality risk of patients is also proposed.
Changing the focus from process monitoring, we have proposed a set of risk-
adjusted test procedures which alleviate the problem of interpretation through
the use of penalty-reward scores. Other risk-adjusted method, specifically the
logistic regression is also discussed. However, the use of these test procedures
require a model between the mortality rates and mortality risks to be specified.
The evaluation of whether a model is wrongly used is not trivial. As such, we
have proposed a model-free diagnostic technique to evaluate the effectiveness of
the clinical procedure by investigating the mortality rates and resulting odds ratio
function against the mortality risks.
Lastly, we presented some facts and myths on the usage of SMR. The var-
ious limitations of using the SMR is adequately discussed with various possibly
wrong interpretations being highlighted. The theoretical estimates of the mean
and variance for SMR are also derived.
For future works, one could develop possibly a distribution-free overall quality
indicator that truly adjusts for mortality risks and a criterion to determine the
efficiency of quality indicators are. These works can be extended beyond medical
field to other fields, as well as accommodate other than Bernoulli outcomes.
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APPENDIX A: RISK-ADJUSTED CUSUM CHART TO MONITOR
CLINICAL PERFORMANCES
This monitoring scheme will be conducted sequentially after the clinical pro-
cedure is implemented on each patient. If we let y to be the post-procedural
outcome for a patient, it corresponds to one of two possible outcomes (success or
failure). We assume yt is the outcome for patient t. (1 if there is a mortality
or 0 if a patient survives after implementation of the clinical procedure). Notice
that the outcome of the clinical procedure may not be observed immediately after
its implementation, with one example being that for cardiac operations in which
the outcome of mortality is usually determined within 30 days from surgery. We
obtained the following probability function of yt, f(yt|p) = pyt [1 − p]1−yt , where
p is the mortality rate.
The risk-adjusted CUSUM chart is formulated based on testing the odds ratio
of the mortality of a patient, where H0 : odds ratio = Q0 versus HA : odds ratio
= QA. This is equivalent to testing H0 : p0(xt)/[1 − p0(xt)] = Q0xt/(1 − xt)
versus HA : pA(xt)/[1 − pA(xt)] = QAxt/(1 − xt) with xt being the mortality
risk for patient t and the mortality rates p0(xt) and pA(xt) are functions of the
mortality risk xt. For a fixed value of xt, these mortality rates p0(xt) and pA(xt)














, if yt = 0.
(A1)
The CUSUM test statistic St, calculated using data up to and including patient
t, is St = max{0, St−1 + Wt} where S0 = 0, with a lower holding barrier at 0
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which is due to the fact that the acceptance of H0 is not of primary interest under
practicality of continual monitoring.
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APPENDIX B: CUMULATIVE SUM CHART TO MONITOR
MORTALITY RISK DISTRIBUTION
Since the mortality risk xt is between 0 and 1, and from previous studies of
the mortality risk distribution, its theoretical model distribution may be modeled
as beta(α,β). Morgan and Henrion (1990) and Moitra (1990) pointed out that
the use of beta distributions in modeling data in the form of proportions is due
to its large variety of shapes. Moreover, Hakes and Viscusi (1997) also discussed
that since the beta distribution is flexible and can assume a vast variety of skewed
and symmetric shapes, its use is not notably restrictive. However, it is also noted
that our proposed charting procedure is not confined to the use of only beta
distribution. Through slight modifications, this procedure can be used for other
distributions for the risk.
On another note, past literature has shown that the average mortality risk
of patients undergoing cardiac surgery has been predominantly increasing over
the years. Parsonnet, Bernstein and Gera (1996) demonstrated that when the
Parsonnet model was applied to the patients of the Beth Israel Hospital in Newark,
the average mortality risk of patients had progressively increased by 47.7% in
1994, as compared to that of 6.5 in 1988. The National Adult Cardiac Surgical
Database Report (2001) also showed similar trends when the average mortality
risk of patients in 1999 had increased by 20% over 3 years. Since much literature
has placed great emphasis on the average mortality risk, we propose a cumulative
sum chart to specifically monitor the average mortality risk. We re-parameterize
the beta distribution so as to obtain a distribution with one of the parameter as
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B( µβ1−µ , β)
, (A2)





1−µ−1(1− t)β−1dt, is the beta function. As either of the
two parameters µ and β of the above probability distribution could change, the
CUSUM chart to monitor the average mortality risk will require β to be set as a
constant. The chart is then formulated based on testing the average mortality risk,
where H0 : µ = µ0 versus HA : µ = µ1 where µ0 is the estimated average mortality
risk from Phase I analysis of historical data and µ1 is the shifted average mortality
risk. This is equivalent to testing H0 : f(X;µ, β) = f(X;µ0, β) versus H1 :
f(X;µ, β) = f(X;µ1, β) for all X ∈ [0, 1]. The plotting statistic of the CUSUM
chart for patient t can be derived from the sequential probability ratio test (SPRT)
procedure proposed by Wald (1947) and if distribution of the mortality risk is
modeled by a beta distribution, the probability function of Xt is given by (A2)







and it can be written as
Wt =
Zt(1− µ0)(1− µ1)
β(µ1 − µ0) = log(Xt) +
(1− µ0)(1− µ1)
β(µ1 − µ0) log
{
B( µ0β1−µ0 , β)
B( µ1β1−µ1 , β)
}
. (A4)
For other distributions for the mortality risks, one will just need to derive, using
the corresponding f(Xt) in (A3).
For the detection of an upward shift in the average mortality risk (that is,
µ1 > µ0) and that of a downward shift in the average mortality risk (that is,
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µ1 < µ0), the CUSUM test statistics, calculated using data up to and including
patient t, is:
S+t = max{0, S+t−1 +Wt}, (A5)
S−t = max{0, S−t−1 −Wt}, (A6)
respectively, where S+0 = S
−
0 = 0, with a lower holding barrier at 0 which is due
to the fact that the acceptance of H0 is not of primary interest under practicality
of continual monitoring.
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APPENDIX C: COLLOCATION METHOD
The collocation method is one of the most recent methods proposed to com-
pute the ARL. Knoth (2005) demonstrated that this method is accurate in com-
puting the ARL when the support is not the entire line. For this method, we
consider a CUSUM chart obtained by plotting St = max(0, St−1+Wt) against the
patient number t. Let L(s0) denote the ARL of the CUSUM chart that starts at
S0 = s0, then
L(s0) = 1 + L(0)P (Wt ≤ −s0; θ, d) +
∫ h
0
L(x)fW (x− s0; θ, d)dx (A7)
where θ is the parameter that defines the probability distribution function fW ,
and d is the parameter of interest investigated by the CUSUM chart.
The collocation method is to approximate L(s0) by
N∑
j=1
cjTj(s0), where Tj(.) is
a set ofN independent interpolating functions, and cj ’s are the unknown constants.
To solve for cj ’s, we have to choose a set of N nodes in the domain [0, h], then
solve the resulting system of linear equations, as discussed in Hackbusch (1995).
According to Knoth (2005), the Chebychev polynomials Tj(z) = cos(j arccos(z)),
j = 0, 1, ..., N − 1, z ∈ [−1, 1] provide stable numerical quadratures, the corre-
sponding nodes are called Chebychev nodes: zi = cos(
(2i−1)pi
2N ), i = 1, 2, ..., N and
zi ∈ [−1, 1].
According to (A7), we consider for all j = 1, 2, ..., N Chebychev polynomials
in [0, h]: Tj(z) = cos[(j − 1) arccos( 2z−hh )] and for all i = 1, 2, ..., N Chebychev
nodes in [0, h]: zi = h2 [1 + cos(
(2i−1)pi
2N )]. As Wt has an upper support (u) and
lower support (l), for each zi, we change the interval [0, h] to [l∗,u∗], where l∗ = 0
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if 0 ≥ l + zi and l∗ = l + zi if 0 < l + zi, u∗ = h if h ≤ u + zi and u∗ = u + zi if
h > u+ zi. cj ’s can then be solved using the following system of linear equations:
N∑
j=1










Tj(x)fW (x− zi; θ, d)dx, (A8)
i = 1, 2, ..., N . The integral on the right-hand side can be determined using the
Gauss-Legendre quadratures (Abramowitz and Stegun, 1968).
As discussed earlier, in order to compute the ARL accurately, the collocation
method is adapted using the distribution function ofWt. Suppose the risk-adjusted
CUSUM chart is formulated based on testing the odds ratio of the mortality of
a patient, where H0 : odds ratio = Q0 versus HA : odds ratio = QA. Usually
Q0 = 1, as the estimated risk xt is based on the current conditions before taking
into account the effect of the true performance of the clinical procedure. Consider
the log-likelihood ratio score Wt for patient t given in (A1), we can obtain the
probability distribution function of W using a conditioning approach (see Ross,
2006, page 376 for examples) as:













ew(1−QA) ; θ), −log(QA) < w < 0,
(A9)
for QA > 1 and













ew(1−QA) ; θ), log(QA) < w < 0,
(A10)
for QA < 1, where Q is the actual odds ratio and fX is the probability function
of the mortality risk, with an example given by (A2).
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However in some scenarios, the odds ratio might not be the same across all
levels of mortality risks, but instead it is more likely to be a linear function of the
mortality risk xt. As such, in order to be able to compute the ARL accurately,
the distribution function of Wt under Q0 = 1 and QA(xt) = (b − a)xt + a is also
derived. We define:
for yt = 1,
QA(xt)
1− xt +QA(xt)xt ≤ e
w
⇒ (a− b)ewxt2 + (b− a− aew + ew)xt + a− ew ≤ 0
⇒ c = 1 + a2 − 4b+ 2(b− a)(1 + a)e−w + (b− a)2e−2w






⇒ x11,± = −
1
2ew
± [2(a− b)(1 + a)e
−w − 2(b− a)2e−2w]
4(a− b)√c
for yt = 0,
1
1− xt +QA(xt)xt ≤ e
w
⇒ (a− b)ewxt2 + (1− a)ewxt + 1− ew ≤ 0
⇒ d = [(1 + a)2 − 4b]e2w + 4(b− a)ew







Since QA(xt) ≥ 0,a ≥ 0 and b ≥ 0.
Firstly, we consider a, b ≤ 1, that is QA(xt) ≤ 1.
For a < b, we set w1 = minx∈(0,1){log[ (b−a)x+a1−x+(b−a)x2+ax ]}
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and w2 = maxx∈(0,1){log[ 11−x+(b−a)x2+ax ]}.
We obtain the probability distribution function of W as:








−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,+ ]fX(x2,−; θ)I(x2,+ < 1), 0 ≤ w ≤ w2,
(A11)
For a > b, we obtain the probability distribution function of W as:





−x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ)I(x1,− > 0), w1 ≤ w < 0;
x12,+[
1−x2,+
1−x2,++Q(x2,+)x2,+ ]fX(x2,+; θ), 0 ≤ w ≤ w2,
(A12)
Next, we consider a, b ≥ 1, that is QA(xt) ≥ 1.
For a < b, we set w3 = minx∈(0,1){log[ 11−x+(b−a)x2+ax ]}
and w4 = maxx∈(0,1){log[ b−a)x+a1−x+(b−a)x2+ax ]}.
We obtain the probability distribution function of W as:
fW (w; θ, d) =

−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,− ]fX(x2,−; θ), w3 ≤ w < 0;
−x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ)
+x11,+[
Q(x1,+)x1,+
1−x1,++Q(x1,+)x1,+ ]fX(x1,+; θ)I(x1,+ > 0), 0 ≤ w ≤ w4;
(A13)
For a > b, we obtain the probability distribution function of W as:




1−x2,++Q(x2,+)x2,+ ]fX(x2,+; θ)I(x2,+ < 1)
−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,− ]fX(x2,−; θ), w3 ≤ w < 0;
−x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ), 0 ≤ w ≤ w4;
(A14)
Lastly, we consider the case that there exists some x0 ∈ (0, 1) such that QA(x0) =
(b− a)x0 + a = 1, that is x0 = (1− a)/(b− a).
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For a < b, we obtain the probability distribution function of W as:




1−x1,++Q(x1,+)x1,+ ]fX(x1,+; θ)I(x1,+ < x0)
−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,− ]fX(x2,−; θ)I(x2,− > x0),
max(w1, w3) ≤ w < 0;
x12,+[
1−x2,+
1−x2,++Q(x2,+)x2,+ ]fX(x2,+; θ)I(x2,+ < x0)
−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,− ]fX(x2,−; θ)I(x2,− < x0)
−x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ)I(x1,− > x0)
+x11,+[
Q(x1,+)x1,+
1−x1,++Q(x1,+)x1,+ ]fX(x1,+; θ)I(x1,+ > x0),
0 ≤ w ≤ max(w2, w4);
(A15)
For a > b, we obtain the probability distribution function of W as:





−x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ)I(x1,− > x0)]
+I(x2,− < x0)[x12,+[
1−x2,+
1−x2,++Q(x2,+)x2,+ ]fX(x2,+; θ)I(x2,+ < x0)
−x12,−[ 1−x2,−1−x2,−+Q(x2,−)x2,− ]fX(x2,−; θ)],




−I(x1,− < x0)x11,−[ Q(x1,−)x1,−1−x1,−+Q(x1,−)x1,− ]fX(x1,−; θ),
0 ≤ w ≤ max(w2, w4);
(A16)
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APPENDIX D. INVESTIGATION OF BANDWIDTH PARAMETERS
In the discussion of using kernel-based matching estimators, under the con-
templation of giving higher weights on patients close in terms of the mortality risk
xt whilst lower weights on more distant observations, the kernel function K(·) can
be chosen to be a symmetric, nonnegative, unimodal kernel, typically the Gaussian
with mean of 0 and variance of 1. The Gaussian kernel function can be stream-
lined to obtain robustness to extreme outliers by limiting the support of the kernel,
such as setting it to 0 for distances greater than 2. Alternatively, the kernel func-
tion can be chosen to be the cosine or Epanechnikov functions. Silverman (1981)
showed that apart from the theoretical advantages of using the Gaussian kernel
function, such as the inheritance of continuity and differentiability properties for
the estimation, it also has strong computational advantages, such as not involving
any nonlinear optimization procedures.
Consequently, Silverman (1986) stated a “rule of thumb” for the selection
of the optimal bandwidth for using the Gaussian kernel function is h =0.9n−1/5
min{s,IQR/1.34} where IQR is the sample interquartile range and s is the sample
standard deviation. This is suggested because it will, to a high degree of accu-
racy, minimize the integrated mean square error, as shown in Deheuvels (1977).
For many situations, this will be an adequate choice of the bandwidth but for
distributions that have relatively large variance with a small range of preliminary
observations, Chen and Kelton (2006) suggested a minor adjustment, in which
h = 0.9n−1/5min{s, IQR/2.68}. The bandwidth can also be determined using
plug-in methods by Park and Marron (1990), and Sheather and Jones (1991).
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Though the above suggested bandwidths are initially introduced for the estima-
tion of Kernel densities, the bandwidths describe the width of the convolution
kernel used. To a layman, the bandwidth will be an indication of the number of
observations that is to be considered in the neighborhood so as to obtain “an ad-
equate estimator”. As such, we will like to test if the above suggested bandwidths
are applicable in our context.
Using various values of the bandwidth h for the Gaussian kernel function,
examples of the estimates pˆ(xt;h) for a sample data set of size n = 1000, one
under Q = 2 and the other under Q = 0.5 are displayed in Figures A1 and
A2 respectively. The mortality risk xt is simulated from beta distribution which
is parameterized by shape parameters α = 1 and β = 3, while the outcome yt is
simulated from Bernoulli distribution parameterized by p(xt) = Qxt/(1−xt+Qxt).
The basis for determining the parameters and various aspects of the examples as
above is to enable us to simulate examples with distributional characteristics of
the mortality risk which mimics that of a real data set we have discussed.
Broadly speaking, from Figures Figures A1(a)-(c) and Figures A2(a)-(c), a
kernel estimator is likely to under- and oversmooth p(xt) by using various values
of the bandwidth h. The choice of the bandwidth is known to generally involve
a trade-off between variance and bias of the estimator. If a small bandwidth is
used, such as in our examples where h = 0.01 (in Figures A1(a) and A2(a)), we
tend to be able to capture local characteristics of p(xt) but we will not be able to
obtain global characteristics of p(xt). This translates to eliminating the bias but
the resulting variance will be large. By using a large bandwidth, such as in our
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example where h = 0.2 (in Figures A1(b) and A2(b)), the global characteristics
of p(xt) can be obtained but we will lose information of its local characteristics.
Consequently, the variance will be reduced but the bias will also be increased. As
such, we need to evaluate the quality of our estimates and address the above trade-
off. For each value of bandwidth h considered in Figures A1(a)-(c) and Figures
A2(a)-(c), a smoother estimate of the odds ratio function using the MSE criterion
is obtained and this is used to compute pˆ(xt). We observe that the estimates
pˆ(xt) are closest to the true p(xt) through the use of the adjusted bandwidth
h = 0.9n−1/5min{s, IQR/2.68} suggested by Chen and Kelton (2006). This shows
the applicability of this bandwidth in our context.
The plots of odds ratio against the mortality risk xt in Figures A1(d) and
A2(d) also suggest that the odds ratios are indeed constants. The high values of
odds ratio observed for small values of xt in Figure A2(d) is inherent, due to large
values of xt/(1 − xt). As a result, a very small increase in the estimate pˆ(xt;h)
tends to result in a much higher value of odds ratio.
We conduct a simulation study to further show the applicability of the band-
widths suggested by Silverman (1986), and Chen and Kelton (2006) in our context.
For Q = 2 and 0.5, the simulation was replicated 1000 times, resulting in 1000
data sets with each data set comprising n = 1000 subjects. The mortality risk xt
for each subject was drawn from a beta distribution with shape parameters α = 1
and β = 2, 2.5, 3, 4 or 5, while the corresponding discrete outcome was generated
from a Bernoulli distribution with p(xt) = Qxt/(1− xt +Qxt).
Table A1 contains the results of the simulation study. The values of the
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optimal bandwidth h are obtained by finding the value of h that estimates p(xt;h)
which upon the minimization of (3.6), gives an estimate of Qˆ closest to the true
Q. This is done through the use of a tedious grid search. We observe that as the
distribution becomes less skewed to the right (as the shape parameter β increases),
there are more subjects with lower mortality risk and less subjects with higher
mortality risk. As a result, the optimal bandwidth to attain the smallest MSE
decreases. This is readily interpreted because most of the subjects have lower
mortality risk, thus in order to better estimate p(xt) in that region, the required
bandwidth need not be comparatively large. Moreover, we observe that through
the use of the adjusted bandwidth h2 suggested by Chen and Kelton (2006), it
emanates Qˆ at a performance similar to that when using the optimal bandwidth
h. These results support the rationale of using h = 0.9n−1/5min{s, IQR/2.68} in
our context.
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Q = 2
(d)
Figure A1. Unsmoothed Kernel estimate pˆ(xt;h)(equation (3.4), represented by
dashed line), smoothed MSE estimate pˆ(xt) (using equation (3.6), rep-
resented by dotted line) of mortality rate with simulated data of size n =
1000 for (a) h = 0.01, (b) h = 0.2 and (c) h = 0.9 n−1/5 min{s, IQR/2.68}
under Q = 2. The true mortality rate p(xt) is represented by the solid
line. Note that the dotted line and the solid line is almost perfectly
matched. For pˆ(xt;h) obtained using (c), the plot of odds ratio of mor-
tality Q against mortality risk xt is shown in (d).
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Q = 0.5
(d)
Figure A2. Unsmoothed Kernel estimate pˆ(xt;h)(equation (3.4), represented by
dashed line), smoothed MSE estimate pˆ(xt) (using equation (3.6), rep-
resented by dotted line) of mortality rate with simulated data of size n =
1000 for (a) h = 0.01, (b) h = 0.2 and (c) h = 0.9 n−1/5 min{s, IQR/2.68}
under Q = 0.5. The true mortality rate p(xt) is represented by the solid
line. Note that the dotted line and the solid line is almost perfectly
matched. For pˆ(xt;h) obtained using (c), the plot of odds ratio of mor-
tality Q against mortality risk xt is shown in (d).
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Table A1. Analysis of Qˆ and its corresponding standard errors using optimal (h),
Silverman (1986)’s (h1) and, Chen and Kelton (2006)’s (h2) bandwidths.
True Distribution Optimal Qˆ h1 Qˆ1 h2 Qˆ2
Q h (SE∗) (SE∗) (SE∗) (SE∗) (SE∗)
2.0 beta(1,2) 0.0476 2.0000 0.0533 1.9978 0.0307 2.0056
(0.0048) (<0.0001) (0.0048) (<0.0001) (0.0048)
beta(1,2.5) 0.0264 2.0000 0.0483 1.9902 0.0267 2.0000
(0.0042) (<0.0001) (0.0041) (<0.0001) (0.0042)
beta(1,3) 0.0207 1.9847 0.0439 1.9684 0.0233 1.9783
(0.0048) (<0.0001) (0.0047) (<0.0001) (0.0047)
beta(1,4) 0.0159 1.9894 0.0365 1.9722 0.0186 1.9840
(0.0052) (<0.0001) (0.0051) (<0.0001) (0.0051)
beta(1,5) 0.0107 1.9928 0.0309 1.9778 0.0156 1.9882
(0.0061) (<0.0001) (0.0058) (<0.0001) (0.0058)
0.5 beta(1,2) 0.0501 0.4972 0.0533 0.4942 0.0307 0.5059
(0.0014) (<0.0001) (0.0014) (<0.0001) (0.0014)
beta(1,2.5) 0.0490 0.5000 0.0483 0.5045 0.0267 0.5065
(0.0014) (<0.0001) (0.0014) (<0.0001) (0.0014)
beta(1,3) 0.0381 0.5000 0.0439 0.4994 0.0233 0.5011
(0.0016) (<0.0001) (0.0016) (<0.0001) (0.0017)
beta(1,4) 0.0298 0.5000 0.0365 0.4992 0.0186 0.5012
(0.0017) (<0.0001) (0.0017) (<0.0001) (0.0018)
beta(1,5) 0.0153 0.5000 0.0309 0.4974 0.0156 0.4989
(0.0020) (<0.0001) (0.0020) (<0.0001) (0.0020)
SE∗: Standard error of estimate
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